CUMULATIVE SUPPLEMENT 3
March 2011



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

31st EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2011

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

31st EDITION

Cumulative Supplement 3

March 2011

CONTENTS

PAGE

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

31st EDITION

CUMULATIVE SUPPLEMENT 3
March 2011

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 30th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 31st Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
  - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.

- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752)tablets have been determined to be therapeutically

equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper

versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://bookstore.gpo.gov; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2008) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2010	MAR 2011	JUN 2011	SEPT 2011	DEC 2011
DRUG PRODUCTS LISTED	13838	14029			
SINGLE SOURCE	2482 (17.9%)	2477 (17.7%)			
MULTISOURCE	11267 (81.4%)	11463 (81.7%)			
THERAPEUTICALLY EQUIVALENT	11107 (80.3%)	11301 (80.6%)			
NOT THERAPEUTICALLY EQUIVALENT	160 (1.2%)	162 (1.2%)			
EXCEPTIONS[1]	89 (0.6%)	89 (0.6%)			
NEW MOLECULAR ENTITIES APPROVED	8	6			
NUMBER OF APPLICANTS	752	768			

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by “N” is a New Drug Application (NDA or innovator). The application number preceded by an “A” is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.

CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

>D>	AA	CONCORD LABS NJ	325MG;50MG;40MG	A040864	001	Dec 01, 2008	Mar	CAHN
>D>	AA		500MG;50MG;40MG	A040883	001	Dec 23, 2008	Mar	CAHN
>A>	AA	MIRROR PHARMS	325MG;50MG;40MG	A040864	001	Dec 01, 2008	Mar	CAHN
>A>	AA		500MG;50MG;40MG	A040883	001	Dec 23, 2008	Mar	CAHN

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

	AA	WRASER PHARMS LLC	356.4MG;30MG;16MG	A040688	001	Apr 03, 2007	Jan	CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	AA	BOCA PHARMA	300MG;5MG	A090415	001	Jan 24, 2011	Feb	CTEC
	AB		300MG;5MG	A090415	001	Jan 24, 2011	Jan	NEWA
	AA		300MG;7.5MG	A090415	002	Jan 24, 2011	Feb	CTEC
	AB		300MG;7.5MG	A090415	002	Jan 24, 2011	Jan	NEWA
	AA		300MG;10MG	A090415	003	Jan 24, 2011	Feb	CTEC
	AB		300MG;10MG	A090415	003	Jan 24, 2011	Jan	NEWA
>D>	AA	MIKART	300MG;5MG	A040658	001	Jan 19, 2006	Mar	CRLD
>A>	AA	+	300MG;5MG	A040658	001	Jan 19, 2006	Mar	CRLD
	AA		300MG;5MG	A040658	001	Jan 19, 2006	Feb	CTEC
	AA	+	300MG;7.5MG	A040556	002	Mar 24, 2006	Feb	CTEC
	AA	+	300MG;10MG	A040556	001	Jun 23, 2004	Feb	CTEC

LORTAB

	AA	UCB INC	500MG;5MG	A087722	001	Jul 09, 1982	Jan	CAHN

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

>D>	AA	VINTAGE PHARMS	650MG;65MG	A040507	001	Jul 30, 2003	Mar	DISC
>A>		@	650MG;65MG	A040507	001	Jul 30, 2003	Mar	DISC

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVOCET-N 100

		@ XANODYNE PHARM	650MG;100MG	N017122	002		Jan	DISC

DARVOCET-N 50

		@ XANODYNE PHARM	325MG;50MG	N017122	001		Jan	DISC

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

>D>	AB	CONCORD LABS NJ	650MG;100MG	A077821	001	Feb 11, 2008	Mar	CAHN
>D>		CORNERSTONE	325MG;100MG	A076743	001	May 07, 2004	Mar	DISC
>A>		@	325MG;100MG	A076743	001	May 07, 2004	Mar	DISC
>D>	AB		500MG;100MG	A076750	001	Jun 28, 2004	Mar	DISC
>A>		@	500MG;100MG	A076750	001	Jun 28, 2004	Mar	DISC
>A>	AB	MIRROR PHARMS	650MG;100MG	A077821	001	Feb 11, 2008	Mar	CAHN
>D>	AB	TEVA	650MG;100MG	A074119	001	Dec 19, 1994	Mar	DISC
>A>		@	650MG;100MG	A074119	001	Dec 19, 1994	Mar	DISC
>D>	AB	VINTAGE PHARMS	325MG;50MG	A074843	002	Feb 15, 2001	Mar	DISC
>A>		@	325MG;50MG	A074843	002	Feb 15, 2001	Mar	DISC

TABLET; ORAL
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

>D>	AB		VINTAGE PHARMS	650MG;100MG	A074843	001	Feb 12, 1997	Mar	DISC
>A>			@	650MG;100MG	A074843	001	Feb 12, 1997	Mar	DISC

ACYCLOVIR

CAPSULE; ORAL
ACYCLOVIR

	AB		MYLAN	200MG	A074977	001	Apr 13, 1998	Feb	CAHN

TABLET; ORAL
ACYCLOVIR

	AB		MYLAN	400MG	A074976	001	Apr 13, 1998	Feb	CAHN
	AB			800MG	A074976	002	Apr 13, 1998	Feb	CAHN

ACYCLOVIR SODIUM

INJECTABLE; INJECTION
ACYCLOVIR SODIUM

			@ HOSPIRA	EQ 50MG BASE/ML	A075065	001	Feb 25, 1999	Feb	DISC

ALCLOMETASONE DIPROPIONATE

OINTMENT; TOPICAL
ACLOVATE

>D>	AB	+	GLAXOSMITHKLINE	0.05%	N018702	001	Dec 14, 1982	Mar	CAHN
>A>	AB	+	NYCOMED US	0.05%	N018702	001	Dec 14, 1982	Mar	CAHN

ALENDRONATE SODIUM

TABLET; ORAL
ALENDRONATE SODIUM

	AB		MYLAN	EQ 35MG BASE	A078638	001	Aug 04, 2008	Feb	CAHN
	AB			EQ 70MG BASE	A078638	002	Aug 04, 2008	Feb	CAHN
>D>	AB		SANDOZ	EQ 5MG BASE	A075871	001	Apr 22, 2009	Mar	DISC
>A>			@	EQ 5MG BASE	A075871	001	Apr 22, 2009	Mar	DISC
>D>	AB			EQ 10MG BASE	A075871	002	Apr 22, 2009	Mar	DISC
>A>			@	EQ 10MG BASE	A075871	002	Apr 22, 2009	Mar	DISC
>D>	AB			EQ 35MG BASE	A075871	004	Apr 22, 2009	Mar	DISC
>A>			@	EQ 35MG BASE	A075871	004	Apr 22, 2009	Mar	DISC
>D>	AB			EQ 40MG BASE	A075871	003	Apr 22, 2009	Mar	DISC
>A>			@	EQ 40MG BASE	A075871	003	Apr 22, 2009	Mar	DISC
>D>	AB			EQ 70MG BASE	A075871	005	Apr 22, 2009	Mar	DISC
>A>			@	EQ 70MG BASE	A075871	005	Apr 22, 2009	Mar	DISC

ALLOPURINOL

TABLET; ORAL
ALLOPURINOL

	AB		IPCA LABS LTD	100MG	A090637	001	Mar 16, 2011	Feb	NEWA
	AB			300MG	A090637	002	Mar 16, 2011	Feb	NEWA

AMLODIPINE BESYLATE

TABLET; ORAL
AMLODIPINE BESYLATE

>A>	AB		HIKMA PHARMS	EQ 2.5MG BASE	A077771	001	Apr 12, 2011	Mar	NEWA
>A>	AB			EQ 5MG BASE	A077771	002	Apr 12, 2011	Mar	NEWA
>A>	AB			EQ 10MG BASE	A077771	003	Apr 12, 2011	Mar	NEWA

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL
LOTREL

AB		NOVARTIS	EQ 5MG BASE;40MG	N020364	007	Apr 11, 2006	Jan	CFTG
AB	+		EQ 10MG BASE;40MG	N020364	006	Apr 11, 2006	Jan	CFTG

AMOXICILLIN

CAPSULE; ORAL
AMOXICILLIN

AB		AM ANTIBIOTICS	250MG	A062058	001		Feb	CDFR
AB			500MG	A062058	002		Feb	CDFR

ANASTROZOLE

TABLET; ORAL
ANASTROZOLE

AB		SANTOS BIOTECH	1MG	A078944	001	Jun 28, 2010	Feb	CAHN

ASPIRIN; CARISOPRODOL

TABLET; ORAL
CARISOPRODOL AND ASPIRIN

>D>	AB	CONCORD LABS NJ	325MG;200MG	A040832	001	Jan 07, 2010	Mar	CAHN
>A>	AB	MIRROR PHARMS	325MG;200MG	A040832	001	Jan 07, 2010	Mar	CAHN
	AB	PROSAM LABS	325MG;200MG	A040252	001	Dec 10, 1997	Feb	CAHN

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

>D>	AB	CONCORD LABS NJ	325MG;200MG;16MG	A040860	001	Jan 07, 2010	Mar	CAHN
>A>	AB	MIRROR PHARMS	325MG;200MG;16MG	A040860	001	Jan 07, 2010	Mar	CAHN
	AB	PROSAM LABS	325MG;200MG;16MG	A040283	001	Dec 29, 1998	Feb	CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL
OXYCODONE AND ASPIRIN

	AA	COASTAL PHARMS	325MG;4.8355MG	A091670	001	Mar 16, 2011	Feb	NEWA
>A>	AA	WATSON LABS	325MG;4.8355MG	A090084	001	Mar 22, 2011	Mar	NEWA

PERCODAN

AA	+	ENDO PHARMS	325MG;4.8355MG	N007337	007	Aug 05, 2005	Feb	CFTG

ATENOLOL

TABLET; ORAL
ATENOLOL

AB		MYLAN	25MG	A074126	003	Aug 26, 1998	Feb	CAHN
AB			50MG	A074126	001	Mar 23, 1994	Feb	CAHN
AB			100MG	A074126	002	Mar 23, 1994	Feb	CAHN

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

AB		GLENMARK GENERICS	250MG;100MG	A091211	001	Jan 12, 2011	Jan	NEWA

MALARONE

AB	+	GLAXOSMITHKLINE	250MG;100MG	N021078	001	Jul 14, 2000	Jan	CFTG

AZILSARTAN MEDOXOMIL

TABLET; ORAL

EDARBI

		TAKEDA PHARMS	40MG	N200796	001	Feb 25, 2011	Feb	NEWA
	+		80MG	N200796	002	Feb 25, 2011	Feb	NEWA

AZTREONAM

INJECTABLE; INJECTION

AZTREONAM

>A>	AP	BEDFORD	1GM/VIAL	A065286	001	Mar 23, 2011	Mar	NEWA
>A>	AP		2GM/VIAL	A065286	002	Mar 23, 2011	Mar	NEWA

BACITRACIN

OINTMENT; OPHTHALMIC

BACITRACIN

	+	FERA PHARMS	500 UNITS/GM	A061212	001		Feb	CAHN
	+	NYCOMED US	500 UNITS/GM	A061212	001		Jan	CAHN

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

AT		FERA PHARMS	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060764	002		Feb	CAHN
AT		NYCOMED US	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060764	002		Jan	CAHN

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT		FERA PHARMS	500 UNITS/GM;10,000 UNITS/GM	A065022	001	Feb 27, 2002	Feb	CAHN
AT		NYCOMED US	500 UNITS/GM;10,000 UNITS/GM	A065022	001	Feb 27, 2002	Jan	CAHN

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

	+	FERA PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166	002		Feb	CAHN
	+	NYCOMED US	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166	002		Jan	CAHN

BACLOFEN

INJECTABLE; INTRATHECAL

GABLOFEN

AP		CNS THERAPS INC	0.05MG/ML	N022462	001	Nov 19, 2010	Feb	CTEC
AP			0.5MG/ML	N022462	002	Nov 19, 2010	Feb	CTEC
AP			2MG/ML	N022462	003	Nov 19, 2010	Feb	CTEC

LIORESAL

AP	+	MEDTRONIC	0.05MG/ML	N020075	003	Nov 07, 1996	Feb	CTEC
AP	+		0.5MG/ML	N020075	001	Jun 17, 1992	Feb	CTEC
AP	+		2MG/ML	N020075	002	Jun 17, 1992	Feb	CTEC

TABLET; ORAL

BACLOFEN

AB		PROSAM LABS	10MG	A077089	001	Oct 31, 2007	Feb	CAHN
AB			20MG	A077088	001	Oct 31, 2007	Feb	CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		MYLAN	5MG;6.25MG	A076612	001	Feb 11, 2004	Feb	CAHN
AB			10MG;12.5MG	A076612	002	Feb 11, 2004	Feb	CAHN
AB			20MG;12.5MG	A076612	003	Feb 11, 2004	Feb	CAHN
AB			20MG;25MG	A076612	004	Feb 11, 2004	Feb	CAHN

BENZTROPINE MESYLATE

INJECTABLE; INJECTION
BENZTROPINE MESYLATE

AP		LUITPOLD	1MG/ML	A091152	001	Mar 29, 2010	Feb	CAHN

BICALUTAMIDE

TABLET; ORAL
BICALUTAMIDE

>A>	AB	ROXANE	50MG	A078285	001	Mar 24, 2011	Mar	NEWA

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC
BROMDAY

>D>		ISTA PHARMS	0.09%	N021664	002	Oct 16, 2010	Mar	CRLD
>A>	+	ISTA PHARMS INC	0.09%	N021664	002	Oct 16, 2010	Mar	CRLD

XIBROM

>D>	+	ISTA PHARMS	0.09%	N021664	001	Mar 24, 2005	Mar	DISC
>A>	@	ISTA PHARMS INC	0.09%	N021664	001	Mar 24, 2005	Mar	DISC

CALCIPOTRIENE

SOLUTION; TOPICAL
CALCIPOTRIENE

>A>	AT	G AND W LABS INC	0.005%	A078468	001	Mar 24, 2011	Mar	NEWA

CALCIUM ACETATE

TABLET; ORAL
CALCIUM ACETATE

>A>	AB	PADDOCK LABS	EQ 160MG CALCIUM	A091561	001	Apr 13, 2011	Mar	NEWA

ELIPHOS

>D>	+	CYPRESS PHARM	EQ 169MG CALCIUM	A078502	001	Nov 25, 2008	Mar	CTEC
>A>	AB +		EQ 169MG CALCIUM	A078502	001	Nov 25, 2008	Mar	CTEC

CARBAMAZEPINE

TABLET, CHEWABLE; ORAL
CARBAMAZEPINE

	@	JUBILANT CADISTA	100MG	A071940	001	Feb 01, 1988	Jan	CAHN

CARBIDOPA; LEVODOPA

TABLET; ORAL
SINEMET

AB		MERCK SHARP DOHME	10MG;100MG	N017555	001		Jan	CAHN
AB			25MG;100MG	N017555	003		Jan	CAHN
AB	+		25MG;250MG	N017555	002		Jan	CAHN

TABLET, EXTENDED RELEASE; ORAL
SINEMET CR

AB		MERCK SHARP DOHME	25MG;100MG	N019856	002	Dec 24, 1992	Jan	CAHN
AB	+		50MG;200MG	N019856	001	May 30, 1991	Jan	CAHN

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL

>D>	AA	CONCORD LABS NJ	350MG	A040823	001	Oct 22, 2008	Mar	CAHN
>A>	AA	MIRROR PHARMS	350MG	A040823	001	Oct 22, 2008	Mar	CAHN
	AA	PROSAM LABS	350MG	A040188	001	Mar 07, 1997	Feb	CAHN

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

AP	HOSPIRA INC	EQ 500MG BASE/VIAL	A065226	001	Apr 21, 2005	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065226	002	Apr 21, 2005	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065244	001	Aug 12, 2005	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A065247	001	Aug 12, 2005	Jan	CAHN

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION
CEFEPIME HYDROCHLORIDE

AP	HOSPIRA INC	EQ 500MG BASE/VIAL	A065369	001	Jun 18, 2007	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065369	002	Jun 18, 2007	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065369	003	Jun 18, 2007	Jan	CAHN

CEFOTAXIME SODIUM

INJECTABLE; INJECTION
CEFOTAXIME SODIUM

AP	HOSPIRA INC	EQ 500MG BASE/VIAL	A065290	001	Aug 11, 2006	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065290	002	Aug 11, 2006	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065293	001	Aug 10, 2006	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065290	003	Aug 11, 2006	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065293	002	Aug 10, 2006	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A065292	001	Aug 10, 2006	Jan	CAHN

CEFOXITIN SODIUM

INJECTABLE; INJECTION
CEFOXITIN

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A065313	001	Jan 23, 2006	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065313	002	Jan 23, 2006	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A065312	001	Feb 13, 2006	Jan	CAHN

CEFPODOXIME PROXETIL

TABLET; ORAL
CEFPODOXIME PROXETIL

AB	+ SANDOZ	EQ 200MG BASE	A065462	002	May 28, 2008	Jan	CRLD
	VANTIN						
	@ PHARMACIA AND UPJOHN	EQ 100MG BASE	N050674	001	Aug 07, 1992	Jan	DISC
	@	EQ 200MG BASE	N050674	002	Aug 07, 1992	Jan	DISC

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV
CEFTRIAXONE

AP	HOSPIRA INC	EQ 250MG BASE/VIAL	A065230	001	Aug 02, 2005	Jan	CAHN
AP		EQ 500MG BASE/VIAL	A065230	002	Aug 02, 2005	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065230	003	Aug 02, 2005	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065230	004	Aug 02, 2005	Jan	CAHN

INJECTABLE; INJECTION
CEFTRIAXONE

AP		HOSPIRA INC	EQ 1GM BASE/VIAL	A065231	001	Aug 02, 2005	Jan	CAHN
AP			EQ 2GM BASE/VIAL	A065231	002	Aug 02, 2005	Jan	CAHN
AP			EQ 10GM BASE/VIAL	A065232	001	Aug 02, 2005	Jan	CAHN
AP	+	SANDOZ	EQ 10GM BASE/VIAL	A065168	001	May 17, 2005	Jan	CRLD

CEFUROXIME SODIUM

INJECTABLE; IM-IV
CEFUROXIME SODIUM

>D> AP		HIKMA FARMACEUTICA	EQ 750MG BASE/VIAL	A065048	001	Jan 09, 2004	Mar	CTEC
>A> AB			EQ 750MG BASE/VIAL	A065048	001	Jan 09, 2004	Mar	CTEC
AP		HOSPIRA INC	EQ 750MG BASE/VIAL	A065483	001	Oct 15, 2008	Jan	CAHN

INJECTABLE; INJECTION
CEFUROXIME SODIUM

AP		HOSPIRA INC	EQ 1.5GM BASE/VIAL	A065483	002	Oct 15, 2008	Jan	CAHN
AP			EQ 1.5GM BASE/VIAL	A065503	001	Oct 15, 2008	Jan	CAHN
AP			EQ 7.5GM BASE/VIAL	A065484	001	Oct 15, 2008	Jan	CAHN

CEPHALEXIN

FOR SUSPENSION; ORAL
CEPHALEXIN

		@ ACS DOBFAR	EQ 100MG BASE/ML	A062117	001		Jan	CAHN
AB			EQ 125MG BASE/5ML	A062117	002		Jan	CAHN
AB	+		EQ 250MG BASE/5ML	A062117	003		Jan	CAHN

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL
CHLORHEXIDINE GLUCONATE

AT		LYNE	0.12%	A074291	001	Dec 28, 1995	Feb	CAHN

CHLOROQUINE PHOSPHATE

TABLET; ORAL
CHLOROQUINE PHOSPHATE

AA		NATCO PHARMA LTD	EQ 150MG BASE	A091621	001	Jan 21, 2011	Jan	NEWA
AA			EQ 300MG BASE	A090612	001	Jan 21, 2011	Jan	NEWA

CHOLESTYRAMINE

POWDER; ORAL
QUESTRAN LIGHT

>D> AB		BRISTOL MYERS	EQ 4GM RESIN/PACKET	N019669	001	Dec 05, 1988	Mar	CRLD
>A> AB	+		EQ 4GM RESIN/PACKET	N019669	001	Dec 05, 1988	Mar	CRLD

CICLOPIROX

SHAMPOO; TOPICAL
CICLOPIROX

AT		TARO	1%	A090269	001	Feb 23, 2011	Feb	NEWA

CLINDAMYCIN PHOSPHATE

GEL; TOPICAL
CLINDAGEL

>D> BT		GALDERMA LABS LP	EQ 1% BASE	N050782	001	Nov 27, 2000	Mar	CRLD
>A> BT	+		EQ 1% BASE	N050782	001	Nov 27, 2000	Mar	CRLD

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
CLONIDINE HYDROCHLORIDE

AP	WEST WARD	1MG/10ML (0.1MG/ML)	A200300	001	Jan 26, 2011	Jan	NEWA
AP		5MG/10ML (0.5MG/ML)	A200300	002	Jan 26, 2011	Jan	NEWA

COLCHICINE; PROBENECID

TABLET; ORAL
PROBENECID AND COLCHICINE

>D> AB	CONCORD LABS NJ	0.5MG;500MG	A040618	001	May 13, 2008	Mar	CAHN
>A> AB	MIRROR PHARMS	0.5MG;500MG	A040618	001	May 13, 2008	Mar	CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL
CYCLOBENZAPRINE HYDROCHLORIDE

AB	JUBILANT CADISTA	5MG	A077563	001	Apr 19, 2006	Jan	CAHN
AB		10MG	A077563	002	Apr 19, 2006	Jan	CAHN
AB	KVK TECH	5MG	A078048	001	Feb 28, 2011	Feb	NEWA
AB		10MG	A078048	002	Feb 28, 2011	Feb	NEWA
AB	PROSAM LABS	5MG	A077291	001	Feb 03, 2006	Feb	CAHN
AB		10MG	A077209	001	Oct 04, 2005	Feb	CAHN

DESLORATADINE

TABLET; ORAL
DESLORATADINE

AB	DR REDDYS LABS LTD	5MG	A078365	001	Mar 08, 2011	Feb	NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28
EMOQUETTE

AB	VINTAGE	0.15MG;0.03MG	A076675	001	Feb 25, 2011	Feb	NEWA

DESOXIMETASONE

GEL; TOPICAL
DESOXIMETASONE

AB	VERSAPHARM	0.05%	A090727	001	Mar 10, 2011	Feb	NEWA

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

AT	FERA PHARMS	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062938	001	Jul 31, 1989	Feb	CAHN
AT	NYCOMED US	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062938	001	Jul 31, 1989	Jan	CAHN

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA	AMNEAL PHARMS	15MG/5ML;6.25MG/5ML	A090575	001	Feb 08, 2011	Jan	NEWA

DIPYRIDAMOLE

TABLET; ORAL
DIPYRIDAMOLE

AB	PROSAM LABS	25MG	A040542	001	Apr 21, 2006	Feb	CAHN
AB		50MG	A040542	002	Apr 21, 2006	Feb	CAHN

TABLET; ORAL
DIPYRIDAMOLE

	AB	PROSAM LABS	75MG	A040542	003	Apr 21, 2006	Feb	CAHN

DISULFIRAM

TABLET; ORAL
ANTABUSE

>D>		ODYSSEY PHARMS	250MG	A088482	001	Dec 08, 1983	Mar	CTEC
>A>	AB		250MG	A088482	001	Dec 08, 1983	Mar	CTEC
>D>	+		500MG	A088483	001	Dec 08, 1983	Mar	CTEC
>A>	AB +		500MG	A088483	001	Dec 08, 1983	Mar	CTEC

DISULFIRAM

>A>	AB	SIGMAPHARM LABS LLC	250MG	A091619	001	Mar 28, 2011	Mar	NEWA
>A>	AB		500MG	A091619	002	Mar 28, 2011	Mar	NEWA

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL
DIVALPROEX SODIUM

>A>	AB	MYLAN	EQ 125MG VALPROIC ACID	A090407	001	Mar 28, 2011	Mar	NEWA

TABLET, DELAYED RELEASE; ORAL
DIVALPROEX SODIUM

>A>	AB	UNICHEM LABS LTD	EQ 125MG VALPROIC ACID	A079163	001	Apr 05, 2011	Mar	NEWA
>A>	AB		EQ 250MG VALPROIC ACID	A079163	002	Apr 05, 2011	Mar	NEWA
>A>	AB		EQ 500MG VALPROIC ACID	A079163	003	Apr 05, 2011	Mar	NEWA
	AB	WATSON LABS FLORIDA	EQ 500MG BASE VALPROIC ACID	A079080	001	Feb 25, 2011	Feb	NEWA

DOCETAXEL

INJECTABLE; INJECTION
>A> DOCETAXEL

>A>	+	HOSPIRA INC	20MG/2ML (10MG/ML)	N022234	001	Mar 08, 2011	Mar	NEWA
>A>	+		80MG/8ML (10MG/ML)	N022234	002	Mar 08, 2011	Mar	NEWA
>A>	+		160MG/16ML (10MG/ML)	N022234	003	Mar 08, 2011	Mar	NEWA

TAXOTERE

>D>	+	SANOFI AVENTIS US	EQ 40MG BASE/ML	N020449	001	May 14, 1996	Mar	DISC
>A>	@		40MG/ML	N020449	001	May 14, 1996	Mar	DISC

DOXYCYCLINE

CAPSULE; ORAL
DOXYCYCLINE

	AB	IMPAX LABS INC	EQ 150MG BASE	A200065	001	Feb 17, 2011	Jan	NEWA
	AB	MYLAN	40MG	A090855	001	Jul 01, 2010	Jan	CDFR
	AB +	PAR PHARM	EQ 150MG BASE	A065055	003	Jul 15, 2005	Feb	CTEC
	AB +		EQ 150MG BASE	A065055	003	Jul 15, 2005	Jan	CTEC

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL
>A> LORYNA

>A>	AB	SANDOZ	3MG;0.02MG	A079221	001	Mar 28, 2011	Mar	NEWA

TABLET; ORAL-28
>A> SYEDA

>A>	AB	SANDOZ	3MG;0.03MG	A090114	001	Mar 28, 2011	Mar	NEWA

ENOXAPARIN SODIUM

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS
LOVENOX

		SANOFI AVENTIS US	300MG/3ML (100MG/ML)	N020164	009	Jan 23, 2003	Feb	CDFR

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ELESTAT

AT	+	ALLERGAN	0.05%	N021565	001	Oct 16, 2003	Feb	CFTG

EPINASTINE HYDROCHLORIDE

AT		CYPRESS PHARM	0.05%	A090870	001	Mar 14, 2011	Feb	NEWA

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYTHROMYCIN

AB		ARBOR PHARMS INC	250MG	A062746	001	Dec 22, 1986	Jan	CAHN

OINTMENT; OPHTHALMIC

ERYTHROMYCIN

AT	+	FERA PHARMS	0.5%	A062447	001	Sep 26, 1983	Feb	CAHN
AT	+	NYCOMED US	0.5%	A062447	001	Sep 26, 1983	Jan	CAHN

SOLUTION; TOPICAL

ERYDERM

	@	ARBOR PHARMS INC	2%	A062290	001		Jan	CAHN

TABLET; ORAL

ERYTHROMYCIN

		ARBOR PHARMS INC	250MG	A061621	001		Jan	CAHN
	+		500MG	A061621	002		Jan	CAHN

TABLET, COATED PARTICLES; ORAL

PCE

		ARBOR PHARMS INC	333MG	N050611	001	Sep 09, 1986	Jan	CAHN
	+		500MG	N050611	002	Aug 22, 1990	Jan	CAHN

TABLET, DELAYED RELEASE; ORAL

E-MYCIN

	@	ARBOR PHARMS INC	250MG	A060272	001		Jan	CAHN
	@		333MG	A060272	002		Jan	CAHN

ERY-TAB

	+	ARBOR PHARMS INC	250MG	A062298	001		Jan	CAHN
	+		333MG	A062298	003	Mar 29, 1982	Jan	CAHN
	+		500MG	A062298	002		Jan	CAHN

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL

E.E.S.

AB		ARBOR PHARMS INC	EQ 200MG BASE/5ML	N050207	001		Jan	CAHN

ERYPED

AB		ARBOR PHARMS INC	EQ 200MG BASE/5ML	N050207	003	Mar 30, 1987	Jan	CAHN
	+		EQ 400MG BASE/5ML	N050207	002		Jan	CAHN

SUSPENSION; ORAL

E.E.S. 200

AB		ARBOR PHARMS INC	EQ 200MG BASE/5ML	A061639	001		Jan	CAHN

E.E.S. 400

AB	+	ARBOR PHARMS INC	EQ 400MG BASE/5ML	A061639	002		Jan	CAHN

PEDIAMYCIN

AB		ARBOR PHARMS INC	EQ 200MG BASE/5ML	A062304	001		Jan	CAHN

PEDIAMYCIN 400

AB		ARBOR PHARMS INC	EQ 400MG BASE/5ML	A062304	002		Jan	CAHN

TABLET; ORAL

E.E.S. 400

	@	ARBOR PHARMS INC	EQ 400MG BASE	A061905	001		Jan	CAHN
BX	+		EQ 400MG BASE	A061905	002	Aug 12, 1982	Jan	CAHN

		TABLET; ORAL							
		ERYTHROMYCIN ETHYLSUCCINATE							
	BX	+ ARBOR PHARMS INC	EQ 400MG BASE	A061904	001			Jan	CAHN
		TABLET, CHEWABLE; ORAL							
		E.E.S.							
		@ ARBOR PHARMS INC	EQ 200MG BASE	N050297	002			Jan	CAHN
		ERYPED							
		@ ARBOR PHARMS INC	EQ 200MG BASE	N050297	003	Jul 05, 1988		Jan	CAHN
		ERYTHROMYCIN STEARATE							
		TABLET; ORAL							
		ERYTHROCIN STEARATE							
		@ ARBOR PHARMS INC	EQ 125MG BASE	A060359	002			Jan	CAHN
			EQ 250MG BASE	A060359	001			Jan	CAHN
		+	EQ 500MG BASE	A060359	003			Jan	CAHN
		ESTRADIOL; NORETHINDRONE ACETATE							
		TABLET; ORAL							
		ACTIVELLA							
>D>		NOVO NORDISK INC	0.5MG;0.1MG	N020907	002	Dec 28, 2006		Mar	CTEC
>A>	AB		0.5MG;0.1MG	N020907	002	Dec 28, 2006		Mar	CTEC
		ESTRADIOL AND NORETHINDRONE ACETATE							
>A>	AB	BRECKENRIDGE PHARM	0.5MG;0.1MG	A078324	002	Apr 04, 2011		Mar	NEWA
		ETHINYL ESTRADIOL; NORETHINDRONE							
		TABLET; ORAL-28							
>A>		BRIELLYN							
>A>	AB	GLENMARK GENERICS	0.035MG;0.4MG	A090538	001	Mar 22, 2011		Mar	NEWA
		TABLET, CHEWABLE; ORAL							
		NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
		+ WARNER CHILCOTT	0.025MG;0.8MG	N022573	001	Dec 22, 2010		Jan	CRLD
		ETHINYL ESTRADIOL; NORETHINDRONE ACETATE							
		TABLET; ORAL-28							
		GILDESS FE 1.5/30							
	AB	VINTAGE	0.03MG;1.5MG	A077075	001	Apr 28, 2005		Jan	CTNA
		GILDESS FE 1/20							
	AB	VINTAGE	0.02MG;1MG	A077077	001	May 20, 2005		Jan	CTNA
		ETHINYL ESTRADIOL; NORGESTIMATE							
		TABLET; ORAL-28							
		NORGESTIMATE AND ETHINYL ESTRADIOL							
	AB	WATSON LABS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A090479	001	Mar 09, 2011		Feb	NEWA
		ETODOLAC							
		CAPSULE; ORAL							
		ETODOLAC							
		@ MYLAN	200MG	A075071	001	Sep 30, 1998		Feb	CAHN
		@	300MG	A075071	002	Sep 30, 1998		Feb	CAHN
		TABLET; ORAL							
		ETODOLAC							
		@ MYLAN	400MG	A075012	001	Sep 30, 1998		Feb	CAHN
		@	500MG	A075012	002	Sep 30, 1998		Feb	CAHN

ETRAVIRINE

TABLET; ORAL

		INTELENCE							
		TIBOTEC	100MG	N022187	001	Jan 18, 2008	Jan	CRLD
	+		200MG	N022187	002	Dec 22, 2010	Jan	NEWA

EXEMESTANE

TABLET; ORAL

		AROMASIN							
>D>	+	PHARMACIA AND UPJOHN	25MG	N020753	001	Oct 21, 1999	Mar	CFTG
>A> AB	+		25MG	N020753	001	Oct 21, 1999	Mar	CFTG
>A>		EXEMESTANE							
>A> AB		ROXANE	25MG	A077431	001	Apr 01, 2011	Mar	NEWA

FAMCICLOVIR

TABLET; ORAL

		FAMCICLOVIR							
>A> AB		AUROBINDO PHARMA LTD	125MG	A091114	001	Mar 21, 2011	Mar	NEWA
>A> AB			250MG	A091114	002	Mar 21, 2011	Mar	NEWA
>A> AB			500MG	A091114	003	Mar 21, 2011	Mar	NEWA
>A> AB		MYLAN	125MG	A201333	001	Mar 24, 2011	Mar	NEWA
>A> AB			250MG	A201333	002	Mar 24, 2011	Mar	NEWA
>A> AB			500MG	A201333	003	Mar 24, 2011	Mar	NEWA
>A> AB		ROXANE	125MG	A090128	001	Mar 21, 2011	Mar	NEWA
>A> AB			250MG	A090128	002	Mar 21, 2011	Mar	NEWA
>A> AB			500MG	A090128	003	Mar 21, 2011	Mar	NEWA
>A> AB		WATSON LABS	125MG	A078278	001	Mar 21, 2011	Mar	NEWA
>A> AB			250MG	A078278	002	Mar 21, 2011	Mar	NEWA
>A> AB			500MG	A078278	003	Mar 21, 2011	Mar	NEWA

FAMOTIDINE

INJECTABLE; INJECTION

		PEPCID							
		@ MERCK	10MG/ML	N019510	001	Nov 04, 1986	Jan	DISC
		PEPCID PRESERVATIVE FREE							
		@ MERCK	10MG/ML	N019510	004	Nov 04, 1986	Jan	DISC
		PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER							
		@ MERCK	0.4MG/ML	N020249	001	Feb 18, 1994	Jan	DISC

TABLET; ORAL

		FAMOTIDINE							
AB		MYLAN	20MG	A075457	001	Apr 18, 2001	Feb	CAHN
AB			40MG	A075457	002	Apr 18, 2001	Feb	CAHN

FENOFIBRATE

TABLET; ORAL

		FENOGLIDE							
		SHORE THERAP	40MG	N022118	001	Aug 10, 2007	Feb	CAHN
	+		120MG	N022118	002	Aug 10, 2007	Feb	CAHN

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

		FENTANYL-100							
AB		MALLINCKRODT INC	100MCG/HR	A077154	004	Feb 09, 2011	Jan	NEWA
		FENTANYL-25							
AB		MALLINCKRODT INC	25MCG/HR	A077154	001	Feb 09, 2011	Jan	NEWA

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-50

AB	MALLINCKRODT INC	50MCG/HR	A077154	002	Feb 09, 2011	Jan	NEWA

FENTANYL-75

AB	MALLINCKRODT INC	75MCG/HR	A077154	003	Feb 09, 2011	Jan	NEWA

FENTANYL CITRATE

TABLET; SUBLINGUAL

ABSTRAL

	PROSTRAKAN INC	EQ 0.1MG BASE	N022510	001	Jan 07, 2011	Jan	NEWA
		EQ 0.2MG BASE	N022510	002	Jan 07, 2011	Jan	NEWA
		EQ 0.3MG BASE	N022510	003	Jan 07, 2011	Jan	NEWA
+		EQ 0.4MG BASE	N022510	004	Jan 07, 2011	Jan	NEWA
		EQ 0.6MG BASE	N022510	005	Jan 07, 2011	Jan	NEWA
		EQ 0.8MG BASE	N022510	006	Jan 07, 2011	Jan	NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

	DR REDDYS LABS LTD	180MG;240MG	A079043	001	Mar 17, 2010	Jan	CTEC

FLUCONAZOLE

TABLET; ORAL

FLUCONAZOLE

AB	AMNEAL PHARM	50MG	A078423	001	Mar 07, 2011	Feb	NEWA
AB		100MG	A078423	002	Mar 07, 2011	Feb	NEWA
AB		150MG	A078423	003	Mar 07, 2011	Feb	NEWA
AB		200MG	A078423	004	Mar 07, 2011	Feb	NEWA
AB	MYLAN	50MG	A076042	001	Jul 29, 2004	Feb	CAHN
AB		100MG	A076042	002	Jul 29, 2004	Feb	CAHN
AB		150MG	A076042	003	Jul 29, 2004	Feb	CAHN
AB		200MG	A076042	004	Jul 29, 2004	Feb	CAHN

FLUDARABINE PHOSPHATE

TABLET; ORAL

OFORTA

	@ SANOFI AVENTIS US	10MG	N022273	001	Dec 18, 2008	Jan	DISC

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP	+ FEINSTEIN	20-200mCi/ML	N021870	001	Aug 19, 2005	Feb	CTEC
AP	PETNET	20-200mCi/ML	A079086	001	Feb 25, 2011	Feb	NEWA

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

>D> AP	+ VALEANT	500MG/10ML (50MG/ML)	N012209	001		Mar	DISC
>A>	+ @	500MG/10ML (50MG/ML)	N012209	001		Mar	DISC

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

AB	MYLAN	125MG	A076224	001	May 09, 2003	Feb	CAHN

FLUVOXAMINE MALEATE

TABLET; ORAL
FLUVOXAMINE MALEATE

	@ MYLAN	50MG	A075950	001	Oct 15, 2001	Feb	CAHN
	@	100MG	A075950	002	Oct 15, 2001	Feb	CAHN

FOLIC ACID

TABLET; ORAL
FOLIC ACID

AA	JUBILANT CADISTA	1MG	A040514	001	Jun 14, 2005	Jan	CAHN

FOSINOPRIL SODIUM

TABLET; ORAL
FOSINOPRIL SODIUM

>A> AB	AUROBINDO PHARMA LTD	10MG	A091163	001	Mar 30, 2011	Mar	NEWA
>A> AB		20MG	A091163	002	Mar 30, 2011	Mar	NEWA
>A> AB		40MG	A091163	003	Mar 30, 2011	Mar	NEWA

GABAPENTIN

CAPSULE; ORAL
GABAPENTIN

AB	MATRIX LABS LTD	100MG	A090158	001	Feb 14, 2011	Jan	NEWA
AB		300MG	A090158	002	Feb 14, 2011	Jan	NEWA
AB		400MG	A090158	003	Feb 14, 2011	Jan	NEWA

SOLUTION; ORAL
GABAPENTIN

AA	HI TECH PHARMA	250MG/5ML	A078974	001	Feb 18, 2011	Feb	NEWA

NEURONTIN

AA +	PARKE DAVIS	250MG/5ML	N021129	001	Mar 02, 2000	Feb	CFTG

TABLET; ORAL
GABAPENTIN

AB	ZYDUS PHARMS USA INC	600MG	A078926	001	Feb 11, 2011	Jan	NEWA
AB		800MG	A078926	002	Feb 11, 2011	Jan	NEWA

GRALISE

BX +	ABBOTT PRODS	300MG	N022544	001	Jan 28, 2011	Jan	NEWA
BX +		600MG	N022544	002	Jan 28, 2011	Jan	NEWA

>A> GADOBUTROL

>A> SOLUTION; INTRAVENOUS
>A> GADAVIST

>A> +	BAYER HLTHCARE	4.5354GM/7.5ML (604.72MG/ML)	N201277	001	Mar 14, 2011	Mar	NEWA
>A> +		6.0472GM/10ML (604.72MG/ML)	N201277	002	Mar 14, 2011	Mar	NEWA
>A> +		9.0708GM/15ML (604.72MG/ML)	N201277	003	Mar 14, 2011	Mar	NEWA
>A> +		18.1416GM/30ML (604.72MG/ML)	N201277	004	Mar 14, 2011	Mar	NEWA
>A> +		39.3068GM/65ML (604.72MG/ML)	N201277	005	Mar 14, 2011	Mar	NEWA

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL
GALANTAMINE HYDROBROMIDE

AB	MYLAN	EQ 8MG BASE	A090900	001	Jan 24, 2011	Jan	NEWA
AB		EQ 16MG BASE	A090900	002	Jan 24, 2011	Jan	NEWA
AB		EQ 24MG BASE	A090900	003	Jan 24, 2011	Jan	NEWA
AB	SUN PHARMA GLOBAL	EQ 8MG BASE	A090178	001	Feb 02, 2011	Jan	NEWA
AB		EQ 16MG BASE	A090178	002	Feb 02, 2011	Jan	NEWA
AB		EQ 24MG BASE	A090178	003	Feb 02, 2011	Jan	NEWA

TABLET; ORAL
GALANTAMINE HYDROBROMIDE

>A>	AB	AUROBINDO PHARMA LTD	EQ 4MG BASE	A090957	001	Mar 29, 2011	Mar	NEWA
>A>	AB		EQ 8MG BASE	A090957	002	Mar 29, 2011	Mar	NEWA
>A>	AB		EQ 12MG BASE	A090957	003	Mar 29, 2011	Mar	NEWA
	AB	ZYDUS PHARMS USA INC	EQ 4MG BASE	A078898	001	Feb 17, 2011	Jan	NEWA
	AB		EQ 8MG BASE	A078898	002	Feb 17, 2011	Jan	NEWA
	AB		EQ 12MG BASE	A078898	003	Feb 17, 2011	Jan	NEWA

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION
GEMCITABINE

	+	HOSPIRA INC	EQ 2GM BASE/VIAL	A079183	001	Nov 15, 2010	Feb	CRLD

GEMCITABINE HYDROCHLORIDE

AP		TEVA PARENTERAL	EQ 200MG BASE/VIAL	A077983	002	Jan 25, 2011	Jan	NEWA
AP			EQ 1GM BASE/VIAL	A077983	001	Jan 25, 2011	Jan	NEWA

GEMZAR

AP	+	LILLY	EQ 200MG BASE/VIAL	N020509	001	May 15, 1996	Jan	CFTG
AP	+		EQ 1GM BASE/VIAL	N020509	002	May 15, 1996	Jan	CFTG

GEMFIBROZIL

TABLET; ORAL
GEMFIBROZIL

AB		BLU CARIBE	600MG	A078012	001	Mar 26, 2007	Feb	CAHN

GENTAMICIN SULFATE

OINTMENT; OPHTHALMIC
GENTAMICIN SULFATE

AT		FERA PHARMS	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Feb	CAHN
AT		NYCOMED US	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Jan	CAHN

SOLUTION/DROPS; OPHTHALMIC
GENTAMICIN SULFATE

AT		FERA PHARMS	EQ 0.3% BASE	A065121	001	Jan 30, 2004	Feb	CAHN

GLIMEPIRIDE

TABLET; ORAL
GLIMEPIRIDE

AB		MYLAN	1MG	A077486	001	Feb 10, 2006	Feb	CAHN
AB			2MG	A077486	002	Feb 10, 2006	Feb	CAHN
AB			4MG	A077486	003	Feb 10, 2006	Feb	CAHN

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL
GLIPIZIDE AND METFORMIN HYDROCHLORIDE

AB		ZYDUS PHARMS USA INC	2.5MG;250MG	A078905	001	Jan 31, 2011	Jan	NEWA
AB			2.5MG;500MG	A078905	002	Jan 31, 2011	Jan	NEWA
AB			5MG;500MG	A078905	003	Jan 31, 2011	Jan	NEWA

GLYBURIDE

TABLET; ORAL
GLYBURIDE

AB		INDICUS PHARMA	1.25MG	A090937	001	Feb 28, 2011	Feb	NEWA
AB			2.5MG	A090937	002	Feb 28, 2011	Feb	NEWA
AB			5MG	A090937	003	Feb 28, 2011	Feb	NEWA

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL

	FULVICIN P/G							
	@ ELORAC	125MG	A061996	001		Jan	CAHN
	@	250MG	A061996	002		Jan	CAHN
	FULVICIN P/G 165							
	@ ELORAC	165MG	A061996	003	Apr 06, 1982	Jan	CAHN
	FULVICIN P/G 330							
	@ ELORAC	330MG	A061996	004	Apr 06, 1982	Jan	CAHN

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

	HYDROCHLOROTHIAZIDE							
AB	JUBILANT CADISTA	12.5MG	A078391	001	Feb 11, 2008	Jan	CAHN

TABLET; ORAL

	HYDROCHLOROTHIAZIDE							
AB	JUBILANT CADISTA	25MG	A040809	001	Sep 04, 2007	Jan	CAHN
AB		50MG	A040809	002	Sep 04, 2007	Jan	CAHN

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

	LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE							
AB	WATSON LABS	12.5MG;50MG	A200180	001	Jan 12, 2011	Jan	NEWA
AB		12.5MG;100MG	A200180	002	Jan 12, 2011	Jan	NEWA
AB		25MG;100MG	A200180	003	Jan 12, 2011	Jan	NEWA

HYDROCORTISONE ACETATE

OINTMENT; OPHTHALMIC

	HYDROCORTISONE ACETATE							
>D>	@ ALTANA	0.5%	A080828	001		Mar	CAHN
>A>	@ FERA PHARMS	0.5%	A080828	001		Mar	CAHN

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL

	HYDROMORPHONE HYDROCHLORIDE							
AB	ELITE LABS	8MG	A076723	001	Oct 18, 2005	Feb	CAHN

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC

	PAREDRINE							
	@ PHARMICS	1%	N000004	004		Jan	CAHN

HYDROXYPROGESTERONE CAPROATE

SOLUTION; INTRAMUSCULAR

	MAKENA							
+	KV PHARM	1250MG/5ML (250MG/ML)	N021945	001	Feb 03, 2011	Feb	NEWA

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

	IDARUBICIN HYDROCHLORIDE							
>A> AP	SANDOZ	1MG/ML	A091293	001	Mar 29, 2011	Mar	NEWA

ILOPERIDONE

TABLET; ORAL
FANAPT

		NOVARTIS	2MG	N022192	002	May 06, 2009	Jan	CAHN
			4MG	N022192	003	May 06, 2009	Jan	CAHN
			6MG	N022192	004	May 06, 2009	Jan	CAHN
			8MG	N022192	005	May 06, 2009	Jan	CAHN
			10MG	N022192	006	May 06, 2009	Jan	CAHN

IMIQUIMOD

CREAM; TOPICAL
IMIQUIMOD

AB		TOLMAR	5%	A091044	001	Feb 28, 2011	Feb	NEWA

INDOMETHACIN

CAPSULE; ORAL
INDOMETHACIN

>A>	AB	HETERO DRUGS LTD	25MG	A091240	001	Apr 12, 2011	Mar	NEWA
>A>	AB		50MG	A091240	002	Apr 12, 2011	Mar	NEWA

CAPSULE, EXTENDED RELEASE; ORAL
INDOMETHACIN

AB	+	SANDOZ	75MG	A074464	001	May 28, 1998	Jan	CTNA

IOFLUPANE I-123

SOLUTION; INTRAVENOUS
DATSCAN

	+	GE HLTHCARE INC	5MCI/2.5ML (2MCI/ML)	N022454	001	Jan 14, 2011	Jan	NEWA

IOPAMIDOL

INJECTABLE; INJECTION
IOPAMIDOL-200

		@ HOSPIRA	41%	A074898	001	Dec 30, 1997	Feb	DISC

IOPAMIDOL-200 IN PLASTIC CONTAINER

		@ HOSPIRA	41%	A074636	001	Dec 30, 1997	Feb	DISC

IOPAMIDOL-250

		@ HOSPIRA	51%	A074898	002	Dec 30, 1997	Feb	DISC

IOPAMIDOL-250 IN PLASTIC CONTAINER

		@ HOSPIRA	51%	A074636	002	Dec 30, 1997	Feb	DISC

IOPAMIDOL-300

		@ HOSPIRA	61%	A074898	003	Dec 30, 1997	Feb	DISC

IOPAMIDOL-300 IN PLASTIC CONTAINER

		@ HOSPIRA	61%	A074636	003	Dec 30, 1997	Feb	DISC

IOPAMIDOL-370

		@ HOSPIRA	76%	A074898	004	Dec 30, 1997	Feb	DISC

IOPAMIDOL-370 IN PLASTIC CONTAINER

		@ HOSPIRA	76%	A074636	004	Dec 30, 1997	Feb	DISC

ISRADIPINE

CAPSULE; ORAL
ISRADIPINE

AB		MIKAH PHARMA	2.5MG	A077169	001	Apr 24, 2006	Feb	CAHN
AB			5MG	A077169	002	Apr 24, 2006	Feb	CAHN

LAMOTRIGINE

TABLET; ORAL
LAMOTRIGINE

>A>	AB	ACTAVIS TOTOWA	25MG	A078669	001	Apr 08, 2011	Mar	NEWA
>A>	AB		100MG	A078669	002	Apr 08, 2011	Mar	NEWA
>A>	AB		150MG	A078669	003	Apr 08, 2011	Mar	NEWA
>A>	AB		200MG	A078669	004	Apr 08, 2011	Mar	NEWA
	AB	ALEMBIC LTD	25MG	A090607	001	Jan 13, 2011	Jan	NEWA
	AB		100MG	A090607	002	Jan 13, 2011	Jan	NEWA
	AB		150MG	A090607	003	Jan 13, 2011	Jan	NEWA
	AB		200MG	A090607	004	Jan 13, 2011	Jan	NEWA

TABLET, CHEWABLE; ORAL
LAMOTRIGINE

AB	JUBILANT LIFE	5MG	A200220	001	Feb 28, 2011	Feb	NEWA
AB		25MG	A200220	002	Feb 28, 2011	Feb	NEWA

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC
LATANOPROST

>A>	AT	ALCON RES	0.005%	A091449	001	Mar 22, 2011	Mar	NEWA
>A>	AT	APOTEX	0.005%	A077697	001	Mar 22, 2011	Mar	NEWA
>A>	AT	BAUSCH AND LOMB	0.005%	A201006	001	Mar 22, 2011	Mar	NEWA
>A>	AT	MYLAN	0.005%	A201786	001	Mar 22, 2011	Mar	NEWA
>A>	AT	PHARMAFORCE	0.005%	A200925	001	Mar 22, 2011	Mar	NEWA

XALATAN

>D>	+	PHARMACIA AND UPJOHN	0.005%	N020597	001	Jun 05, 1996	Mar	CFTG
>A>	AT	+	0.005%	N020597	001	Jun 05, 1996	Mar	CFTG

LEVETIRACETAM

TABLET; ORAL
LEVETIRACETAM

AB	ACCORD HLTHCARE	250MG	A090843	001	Feb 14, 2011	Jan	NEWA
AB		500MG	A090843	002	Feb 14, 2011	Jan	NEWA
AB		750MG	A090843	003	Feb 14, 2011	Jan	NEWA
AB		1GM	A090843	004	Feb 14, 2011	Jan	NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL
LEVOCETIRIZINE DIHYDROCHLORIDE

AB	DR REDDYS LABS LTD	5MG	A090392	001	Feb 24, 2011	Feb	NEWA
AB	GLENMARK GENERICS	5MG	A090385	001	Feb 24, 2011	Feb	NEWA

LEVOFLOXACIN

SOLUTION/DROPS; OPHTHALMIC
LEVOFLOXACIN

AT	HI TECH PHARMA	0.5%	A076826	001	Feb 10, 2011	Jan	NEWA

LEVONORGESTREL

TABLET; ORAL
PLAN B

	@ TEVA WOMENS	0.75MG	N021045	001	Jul 28, 1999	Feb	CAHN
AB	+	0.75MG	N021045	002	Aug 24, 2006	Feb	CAHN

LEVORPHANOL TARTRATE

TABLET; ORAL

>D>			LEVO-DROMORAN							
>D>	AB	+	VALEANT PHARM INTL	2MG	N008720	001	Dec 19, 1991	Mar	DISC
>A>			@	2MG	N008720	001	Dec 19, 1991	Mar	DISC
			LEVORPHANOL TARTRATE							
>D>	AB		ROXANE	2MG	A074278	001	Mar 31, 2000	Mar	CTEC
>A>				2MG	A074278	001	Mar 31, 2000	Mar	CTEC

LEVOTHYROXINE SODIUM**

**Refer to Annual Edition Preface Section 1.8 Levothyroxine Sodium for amplifying information

TABLET; ORAL

		LEVO-T							
AB1, AB2, AB3		ALARA PHARM	0.025MG	N021342	001	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3			0.05MG	N021342	002	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3			0.075MG	N021342	003	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3			0.088MG	N021342	004	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3			0.1MG	N021342	005	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3			0.112MG	N021342	006	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3			0.125MG	N021342	007	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3			0.137MG	N021342	012	Dec 08, 2003	Feb	CTEC
AB1, AB2, AB3			0.15MG	N021342	008	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3			0.175MG	N021342	009	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3			0.2MG	N021342	010	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3	+		0.3MG	N021342	011	Mar 01, 2002	Feb	CTEC

LIDOCAINE HYDROCHLORIDE

JELLY; TOPICAL

		LIDOCAINE HYDROCHLORIDE							
>A>	AT		HI TECH PHARMA	2%	A040837	001	Mar 23, 2011	Mar	NEWA

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL

		LITHIUM CARBONATE							
AB		GLENMARK GENERICS	450MG	A091616	001	Feb 14, 2011	Jan	NEWA

LOSARTAN POTASSIUM

TABLET; ORAL
LOSARTAN POTASSIUM

AB		MYLAN	25MG	A091590	001	Oct 06, 2010	Jan	NEWA
AB			50MG	A091590	002	Oct 06, 2010	Jan	NEWA
AB			100MG	A091590	003	Oct 06, 2010	Jan	NEWA

MECLIZINE HYDROCHLORIDE

TABLET; ORAL
MECLIZINE HYDROCHLORIDE

AA		AMNEAL PHARMS	12.5MG	A201451	001	Feb 23, 2011	Feb	NEWA
AA			25MG	A201451	002	Feb 23, 2011	Feb	NEWA
AA			50MG	A201451	003	Feb 23, 2011	Feb	NEWA
AA		JUBILANT CADISTA	12.5MG	A040659	001	Jun 04, 2010	Jan	CAHN
AA			25MG	A040659	002	Jun 04, 2010	Jan	CAHN

MELOXICAM

TABLET; ORAL
MELOXICAM

AB		MYLAN	7.5MG	A077934	001	Jul 20, 2006	Feb	CAHN
AB			15MG	A077934	002	Jul 20, 2006	Feb	CAHN

MEROPENEM

INJECTABLE; INJECTION
MEROPENEM

>A>	AP	SANDOZ	500MG/VIAL	A091201	001	Mar 29, 2011	Mar	NEWA
>A>	AP		1GM/VIAL	A091201	002	Mar 29, 2011	Mar	NEWA
>A>		MERREM						
>A>	AP +	ASTRAZENECA	500MG/VIAL	N050706	003	Jun 21, 1996	Mar	CTNA
>A>	AP +		1GM/VIAL	N050706	001	Jun 21, 1996	Mar	CTNA
>D>		MERREM I.V.						
>D>	AP +	ASTRAZENECA	500MG/VIAL	N050706	003	Jun 21, 1996	Mar	CTNA
>D>	AP +		1GM/VIAL	N050706	001	Jun 21, 1996	Mar	CTNA

METFORMIN HYDROCHLORIDE

TABLET; ORAL
METFORMIN HYDROCHLORIDE

AB		MYLAN	500MG	A075973	001	Jan 25, 2002	Feb	CAHN
AB			850MG	A075973	002	Jan 25, 2002	Feb	CAHN
AB			1GM	A075973	003	Jan 25, 2002	Feb	CAHN

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL
ACTOPLUS MET

AB		TAKEDA GLOBAL	500MG;EQ 15MG BASE	N021842	001	Aug 29, 2005	Feb	CFTG
AB	+		850MG;EQ 15MG BASE	N021842	002	Aug 29, 2005	Feb	CFTG

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB		MYLAN	500MG;EQ 15MG BASE	A090406	001	Feb 25, 2011	Feb	NEWA
AB			850MG;EQ 15MG BASE	A090406	002	Feb 25, 2011	Feb	NEWA

METHYLPREDNISOLONE

TABLET; ORAL
METHYLPREDNISOLONE

AB		JUBILANT CADISTA	4MG	A040189	001	Oct 31, 1997	Jan	CAHN
AB			8MG	A040189	002	Oct 31, 1997	Jan	CAHN

TABLET; ORAL
METHYLPREDNISOLONE

AB	JUBILANT CADISTA	16MG	A040189	003	Jul 20, 2007	Jan	CAHN
AB		32MG	A040189	004	Jul 20, 2007	Jan	CAHN

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
A-METHAPRED

@	HOSPIRA	EQ 500MG BASE/VIAL	A089173	001	Aug 18, 1987	Feb	DISC
@		EQ 1GM BASE/VIAL	A089174	001	Aug 18, 1987	Feb	DISC

METRONIDAZOLE

GEL; TOPICAL
METRONIDAZOLE

AB	G AND W LABS INC	0.75%	A078178	001	Jan 19, 2011	Jan	NEWA

MICAFUNGIN SODIUM

INJECTABLE; IV (INFUSION)
MYCAMINE

+	ASTELLAS	100MG/VIAL	N021506	003	Jun 27, 2006	Jan	CRLD

MILRINONE LACTATE

INJECTABLE; INJECTION
MILRINONE LACTATE

@	HOSPIRA	EQ 1MG BASE/ML	A075884	001	May 28, 2002	Feb	DISC

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL
MIRTAZAPINE

AB	ACTAVIS ELIZABETH	15MG	A077959	001	Feb 14, 2011	Jan	NEWA
AB		30MG	A077959	002	Feb 14, 2011	Jan	NEWA
AB		45MG	A077959	003	Feb 14, 2011	Jan	NEWA

MUPIROCIN CALCIUM

CREAM; TOPICAL
BACTROBAN

+	GLAXOSMITHKLINE	EQ 2% BASE	N050746	001	Dec 11, 1997	Jan	CDFR

NABUMETONE

TABLET; ORAL
NABUMETONE

AB	LUPIN LTD	500MG	A090445	001	Jan 12, 2011	Jan	NEWA
AB		750MG	A090445	002	Jan 12, 2011	Jan	NEWA

NALTREXONE HYDROCHLORIDE

TABLET; ORAL
NALTREXONE HYDROCHLORIDE

AB	ELITE LABS	50MG	A075274	001	May 26, 1999	Feb	CAHN

NAPROXEN

TABLET; ORAL
NAPROXEN

AB	MARKSANS PHARMA	250MG	A091416	001	Feb 14, 2011	Jan	NEWA
AB		375MG	A091416	002	Feb 14, 2011	Jan	NEWA
AB		500MG	A091416	003	Feb 14, 2011	Jan	NEWA

NARATRIPTAN

TABLET; ORAL
NARATRIPTAN

AB		SUN PHARM INDS LTD	EQ 2.5MG BASE	A091552	001	Feb 14, 2011	Jan	NEWA

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL
NARATRIPTAN

AB		INDICUS PHARMA	EQ 1MG BASE	A200502	001	Feb 28, 2011	Feb	NEWA
AB			EQ 2.5MG BASE	A200502	002	Feb 28, 2011	Feb	NEWA

NATEGLINIDE

TABLET; ORAL
NATEGLINIDE

>A>	AB	WATSON LABS	60MG	A077462	001	Mar 30, 2011	Mar	NEWA
>A>	AB		120MG	A077462	002	Mar 30, 2011	Mar	NEWA

NEVIRAPINE

>A> TABLET, EXTENDED RELEASE; ORAL
>A> VIRAMUNE XR

>A>	+	BOEHRINGER INGELHEIM	400MG	N201152	001	Mar 25, 2011	Mar	NEWA

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL
NISOLDIPINE

AB		MYLAN	8.5MG	A091001	001	Jan 26, 2011	Jan	NEWA
AB			17MG	A091001	002	Jan 26, 2011	Jan	NEWA
AB			25.5MG	A091001	003	Jan 26, 2011	Jan	NEWA
AB			34MG	A091001	004	Jan 26, 2011	Jan	NEWA

SULAR

AB	+	SHIONOGI PHARMA	8.5MG	N020356	008	Jan 02, 2008	Jan	CFTG
AB	+		17MG	N020356	007	Jan 02, 2008	Jan	CFTG
AB			25.5MG	N020356	006	Jan 02, 2008	Jan	CFTG
AB	+		34MG	N020356	005	Jan 02, 2008	Jan	CFTG

NIZATIDINE

CAPSULE; ORAL
NIZATIDINE

AB		MYLAN	150MG	A075934	001	Jul 09, 2002	Feb	CAHN
AB			300MG	A075934	002	Jul 09, 2002	Feb	CAHN

NYSTATIN

SUSPENSION; ORAL
NYSTATIN

AA		VISTAPHARM	100,000 UNITS/ML	A065422	001	Mar 07, 2011	Feb	NEWA

OCTREOTIDE ACETATE

INJECTABLE; INJECTION
OCTREOTIDE ACETATE (PRESERVATIVE FREE)

AP		BIONICHE PHARMA USA	EQ 0.05MG BASE/ML	A079198	001	Feb 10, 2011	Jan	NEWA
AP			EQ 0.1MG BASE/ML	A079198	002	Feb 10, 2011	Jan	NEWA
AP			EQ 0.5MG BASE/ML	A079198	003	Feb 10, 2011	Jan	NEWA

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL
ONDANSETRON

AB	RANBAXY	4MG	A078602	001	Feb 24, 2011	Feb	NEWA
AB		8MG	A078602	002	Feb 24, 2011	Feb	NEWA

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION
ONDANSETRON HYDROCHLORIDE

AP	TEVA	EQ 2MG BASE/ML	A076876	001	Nov 22, 2006	Jan	CMFD

SOLUTION; ORAL
ONDANSETRON HYDROCHLORIDE

AA	AMNEAL PHARMS	EQ 4MG BASE/5ML	A091483	001	Jan 31, 2011	Jan	NEWA
AA	SILARX	EQ 4MG BASE/5ML	A091342	001	Jan 27, 2011	Jan	NEWA

TABLET; ORAL
ONDANSERTRON HYDROCHLORIDE

>A>	AB	TARO	EQ 4MG BASE	A077729	001	Mar 28, 2011	Mar	NEWA
>A>	AB		EQ 8MG BASE	A077729	002	Mar 28, 2011	Mar	NEWA
>A>	AB		EQ 24MG BASE	A077729	003	Mar 28, 2011	Mar	NEWA

OXALIPLATIN

INJECTABLE; IV (INFUSION)
OXALIPLATIN

AP	SANDOZ	50MG/10ML (5MG/ML)	A078817	001	Jan 24, 2011	Jan	NEWA
AP		100MG/20ML (5MG/ML)	A078817	002	Jan 24, 2011	Jan	NEWA

OXAPROZIN

TABLET; ORAL
OXAPROZIN

AB	MYLAN	600MG	A075847	001	Feb 28, 2001	Feb	CAHN

OXYCODONE HYDROCHLORIDE

TABLET; ORAL
OXYCODONE HYDROCHLORIDE

AB	COASTAL PHARMS	5MG	A091313	001	Feb 18, 2011	Feb	NEWA
AB		15MG	A091313	002	Feb 18, 2011	Feb	NEWA
AB		30MG	A091313	003	Feb 18, 2011	Feb	NEWA
AB	RHODES PHARMS	5MG	A091490	001	Mar 09, 2011	Feb	NEWA
AB		10MG	A091490	002	Mar 09, 2011	Feb	NEWA
AB		15MG	A091490	003	Mar 09, 2011	Feb	NEWA
AB		20MG	A091490	004	Mar 09, 2011	Feb	NEWA
AB		30MG	A091490	005	Mar 09, 2011	Feb	NEWA

OXYMORPHONE HYDROCHLORIDE

TABLET; ORAL
OXYMORPHONE HYDROCHLORIDE

AB	TEVA	5MG	A091443	002	Feb 15, 2011	Jan	NEWA
AB		10MG	A091443	001	Feb 15, 2011	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL
OPANA ER

	@ ENDO PHARMS	7.5MG	N021610	005	Feb 29, 2008	Feb	DISC
	@	15MG	N021610	006	Feb 29, 2008	Feb	DISC

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB	ACTAVIS TOTOWA	EQ 20MG BASE	A090797	001	Feb 07, 2011	Jan	NEWA
AB		EQ 40MG BASE	A090797	002	Feb 07, 2011	Jan	NEWA
AB	DR REDDYS LABS LTD	EQ 20MG BASE	A077619	001	Jan 19, 2011	Jan	NEWA
AB		EQ 40MG BASE	A077619	002	Jan 19, 2011	Jan	NEWA
AB	KUDCO IRELAND	EQ 20MG BASE	A078281	001	Jan 20, 2011	Jan	NEWA
AB		EQ 40MG BASE	A078281	002	Jan 20, 2011	Jan	NEWA
AB	MATRIX LABS LTD	EQ 20MG BASE	A090970	001	Jan 19, 2011	Jan	NEWA
AB		EQ 40MG BASE	A090970	002	Jan 19, 2011	Jan	NEWA
AB	TORRENT PHARMS	EQ 20MG BASE	A090074	001	Jan 19, 2011	Jan	NEWA
AB		EQ 40MG BASE	A090074	002	Jan 19, 2011	Jan	NEWA
AB	WOCKHARDT	EQ 20MG BASE	A091231	001	Jan 19, 2011	Jan	NEWA
AB		EQ 40MG BASE	A091231	002	Jan 19, 2011	Jan	NEWA

PHENTERMINE HYDROCHLORIDE

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

AA	EPIC PHARMA LLC	37.5MG	A200272	001	Jan 31, 2011	Jan	NEWA

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

AP	HOSPIRA INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065386	001	Sep 15, 2009	Jan	CAHN
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065386	002	Sep 15, 2009	Jan	CAHN
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065386	003	Sep 15, 2009	Jan	CAHN
AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A065446	001	Sep 15, 2009	Jan	CAHN

PIROXICAM

CAPSULE; ORAL

PIROXICAM

	@ MYLAN	10MG	A074043	001	Sep 22, 1992	Feb	CAHN
	@	20MG	A074043	002	Sep 22, 1992	Feb	CAHN

PREDNISONE

TABLET; ORAL

PREDNISONE

AB	JUBILANT CADISTA	1MG	A040611	001	Jun 06, 2005	Jan	CAHN
AB		5MG	A040362	002	Aug 29, 2001	Jan	CAHN
AB		10MG	A040362	001	Aug 29, 2001	Jan	CAHN
AB		20MG	A040362	003	Jun 29, 2005	Jan	CAHN

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCOMP

AB	JUBILANT CADISTA	EQ 5MG BASE	A040268	001	Feb 27, 1998	Jan	CAHN
AB		EQ 10MG BASE	A040268	002	Feb 27, 1998	Jan	CAHN

PROPANTHELINE BROMIDE

TABLET; ORAL
PROPANTHELINE BROMIDE

+		ROXANE	15MG	A080927	002			Jan	CMFD

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
DARVON

@		XANODYNE PHARM	65MG	N010997	003			Jan	DISC

PROPOXYPHENE HYDROCHLORIDE

>D>	AA	TEVA	65MG	A088615	001	Oct 22, 1984		Mar	DISC
>A>		@	65MG	A088615	001	Oct 22, 1984		Mar	DISC
>D>	AA	VINTAGE PHARMS	65MG	A040908	001	Jul 17, 2009		Mar	DISC
>A>		@	65MG	A040908	001	Jul 17, 2009		Mar	DISC
		@ WEST WARD	65MG	A083501	001			Jan	DISC

PROPOXYPHENE NAPSYLATE

TABLET; ORAL
DARVON-N

@		XANODYNE PHARM	100MG	N016862	002			Jan	DISC

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
PROPRANOLOL HYDROCHLORIDE

>A>	AB	ZYDUS PHARMS USA INC	60MG	A090321	001	Mar 25, 2011		Mar	NEWA
>A>	AB		80MG	A090321	002	Mar 25, 2011		Mar	NEWA
>A>	AB		120MG	A090321	003	Mar 25, 2011		Mar	NEWA
>A>	AB		160MG	A090321	004	Mar 25, 2011		Mar	NEWA

TABLET; ORAL
PROPRANOLOL HYDROCHLORIDE

>A>	AB	MYLAN	60MG	A070213	005	Apr 08, 2011		Mar	NEWA

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL
QUINAPRIL HYDROCHLORIDE

	AB	MYLAN	EQ 5MG BASE	A076036	001	Jan 28, 2005		Feb	CAHN
	AB		EQ 10MG BASE	A076036	002	Jan 28, 2005		Feb	CAHN
	AB		EQ 20MG BASE	A076036	003	Jan 28, 2005		Feb	CAHN
	AB		EQ 40MG BASE	A076036	004	Jan 28, 2005		Feb	CAHN

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL
RANITIDINE HYDROCHLORIDE

@		MYLAN	EQ 150MG BASE	A075564	001	Oct 27, 2000		Feb	CAHN
@			EQ 300MG BASE	A075564	002	Oct 27, 2000		Feb	CAHN

SYRUP; ORAL
RANITIDINE HYDROCHLORIDE

>A>	AA	HI TECH PHARMA	EQ 15MG BASE/ML	A091078	001	Mar 22, 2011		Mar	NEWA

TABLET; ORAL
RANITIDINE HYDROCHLORIDE

	AB	MYLAN	EQ 150MG BASE	A074023	001	Aug 22, 1997		Feb	CAHN
	AB		EQ 300MG BASE	A074023	002	Aug 22, 1997		Feb	CAHN

RIFAXIMIN

TABLET; ORAL
XIFAXAN
\+ SALIX PHARMS 550MG N022554 001 Mar 24, 2010 Feb CRLD

RISPERIDONE

SOLUTION; ORAL
RISPERIDONE
AA TARO 1MG/ML A090347 001 Feb 07, 2011 Jan NEWA

TABLET; ORAL
RISPERIDONE
@ RATIOPHARM 0.25MG A077784 001 Jun 08, 2010 Feb DISC
@ 0.5MG A077784 002 Jun 08, 2010 Feb DISC
@ 1MG A077784 003 Jun 08, 2010 Feb DISC
@ 2MG A077784 004 Jun 08, 2010 Feb DISC
@ 3MG A077784 005 Jun 08, 2010 Feb DISC
@ 4MG A077784 006 Jun 08, 2010 Feb DISC

TABLET, ORALLY DISINTEGRATING; ORAL
RISPERIDONE
>A> AB MYLAN 0.5MG A091537 001 Mar 30, 2011 Mar NEWA
>A> AB 1MG A091537 002 Mar 30, 2011 Mar NEWA
>A> AB 2MG A091537 003 Mar 30, 2011 Mar NEWA
>A> AB 3MG A091537 004 Mar 30, 2011 Mar NEWA
>A> AB 4MG A091537 005 Mar 30, 2011 Mar NEWA

ROCURONIUM BROMIDE

INJECTABLE; INJECTION
ROCURONIUM BROMIDE
AP SAGENT STRIDES 50MG/5ML (10MG/ML) A091458 001 Jul 28, 2010 Jan CAHN
AP 100MG/10ML (10MG/ML) A091458 002 Jul 28, 2010 Jan CAHN

ROFLUMILAST

TABLET; ORAL
DALIRESP
\+ FOREST RES INST INC 500MCG N022522 001 Feb 28, 2011 Feb NEWA

RUFINAMIDE

>A> SUSPENSION; ORAL
>A> BANZEL
>A> \+ EISAI INC 40MG/ML N201367 001 Mar 03, 2011 Mar NEWA

SECOBARBITAL SODIUM

CAPSULE; ORAL
SECONAL SODIUM
\+ MARATHON PHARMS 50MG A086101 001 Oct 03, 1983 Jan CAHN
\+ 100MG A086101 002 Oct 03, 1983 Jan CAHN

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL
SERTRALINE HYDROCHLORIDE
>D> AA ROXANE EQ 20MG BASE/ML A076934 001 Jun 30, 2006 Mar DISC
>A> @ EQ 20MG BASE/ML A076934 001 Jun 30, 2006 Mar DISC

TABLET; ORAL
SERTRALINE HYDROCHLORIDE
AB MYLAN EQ 25MG BASE A076540 001 Mar 20, 2007 Feb CAHN

TABLET; ORAL
SERTRALINE HYDROCHLORIDE

	AB	MYLAN	EQ 50MG BASE	A076540	002	Mar 20, 2007	Feb	CAHN
	AB		EQ 100MG BASE	A076540	003	Mar 20, 2007	Feb	CAHN
>D>	AB	ROXANE	EQ 25MG BASE	A076881	001	Feb 06, 2007	Mar	DISC
>A>		@	EQ 25MG BASE	A076881	001	Feb 06, 2007	Mar	DISC
>D>	AB		EQ 50MG BASE	A076881	002	Feb 06, 2007	Mar	DISC
>A>		@	EQ 50MG BASE	A076881	002	Feb 06, 2007	Mar	DISC
>D>	AB		EQ 100MG BASE	A076881	003	Feb 06, 2007	Mar	DISC
>A>		@	EQ 100MG BASE	A076881	003	Feb 06, 2007	Mar	DISC

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION
FERRLECIT

>D>		+ SANOFI AVENTIS US	62.5MG/5ML	N020955	001	Feb 18, 1999	Mar	CFTG
>A>	AB	+	62.5MG/5ML	N020955	001	Feb 18, 1999	Mar	CFTG
>A>		SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE						
>A>	AB	GENERAMEDIX	62.5MG/5ML	A078215	001	Mar 31, 2011	Mar	NEWA

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS
SODIUM FLUORIDE F 18

		+ NIH NCI DCTD	10-200mCi/ML	N022494	001	Jan 26, 2011	Jan	NEWA

SODIUM NITRITE; SODIUM THIOSULFATE

SOLUTION, SOLUTION; INTRAVENOUS, INTRAVENOUS
NITHIODOTE

		+ HOPE PHARMS	300MG/10ML(30MG/ML),N/A;N/A,12.5GM/50ML(250MG/ML)	N201444	001	Jan 14, 2011	Feb	CTNA

SODIUM NITRITE

		+ HOPE PHARMS	300MG/10ML(30MG/ML),N/A;N/A,12.5GM/50ML(250MG/ML)	N201444	001	Jan 14, 2011	Jan	NEWA

SPINOSAD

SUSPENSION; TOPICAL
NATROBA

		+ PARAPRO PHARMS	0.9%	N022408	001	Jan 18, 2011	Jan	NEWA

SUMATRIPTAN SUCCINATE

TABLET; ORAL
SUMATRIPTAN SUCCINATE

>D>	AB	ROXANE	EQ 25MG BASE	A078241	001	Aug 10, 2009	Mar	DISC
>A>		@	EQ 25MG BASE	A078241	001	Aug 10, 2009	Mar	DISC
>D>	AB		EQ 50MG BASE	A078241	002	Aug 10, 2009	Mar	DISC
>A>		@	EQ 50MG BASE	A078241	002	Aug 10, 2009	Mar	DISC
>D>	AB		EQ 100MG BASE	A078241	003	Aug 10, 2009	Mar	DISC
>A>		@	EQ 100MG BASE	A078241	003	Aug 10, 2009	Mar	DISC

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
TERAZOSIN HYDROCHLORIDE

	AB	JUBILANT CADISTA	EQ 1MG BASE	A075317	001	Dec 20, 2004	Jan	CAHN
	AB		EQ 2MG BASE	A075317	002	Dec 20, 2004	Jan	CAHN
	AB		EQ 5MG BASE	A075317	003	Dec 20, 2004	Jan	CAHN
	AB		EQ 10MG BASE	A075317	004	Dec 20, 2004	Jan	CAHN

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL
TERBINAFINE HYDROCHLORIDE

	AB		MYLAN	EQ 250MG BASE	A077136	001	Jul 02, 2007	Feb CAHN
		@	ROXANE	EQ 250MG BASE	A077223	001	Jul 02, 2007	Feb DISC

TERBUTALINE SULFATE

TABLET; ORAL
TERBUTALINE SULFATE

	AB	+	IMPAX LABS	5MG	A075877	002	Jun 26, 2001	Jan CRLD

TESTOSTERONE

GEL, METERED; TRANSDERMAL
FORTESTA

>D>		+	ENDO PHARMS	10MG/5GM ACTIVATION	N021463	001	Dec 29, 2010	Mar CPOT
>A>		+		10MG/0.5GM ACTIVATION	N021463	001	Dec 29, 2010	Mar CPOT

THEOPHYLLINE

SOLUTION; ORAL
THEOPHYLLINE

>A>		+	SILARX	80MG/15ML	A091156	001	Apr 13, 2011	Mar NEWA

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL
TICLOPIDINE HYDROCHLORIDE

	AB		MYLAN	250MG	A075161	001	Sep 13, 1999	Feb CAHN

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC
TOBRAMYCIN

>D>	AT		ALTANA	0.3%	A065026	001	Sep 11, 2001	Mar CAHN
>A>	AT		FERA PHARMS	0.3%	A065026	001	Sep 11, 2001	Mar CAHN

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
TOPOTECAN HYDROCHLORIDE

	AP		DR REDDYS LABS LTD	EQ 4MG BASE/VIAL	A201191	001	Mar 09, 2011	Feb NEWA
	AP		SAGENT PHARMS	EQ 4MG BASE/VIAL	A091284	001	Jan 26, 2011	Jan NEWA

SOLUTION; INTRAVENOUS
TOPOTECAN

	AP		HOSPIRA INC	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N200582	001	Feb 02, 2011	Feb NEWA
			SANDOZ	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N200199	001	Feb 25, 2011	Feb NEWA
				EQ 3MG BASE/3ML (EQ 1MG BASE/ML)	N200199	002	Feb 25, 2011	Feb NEWA
	AP	+		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N200199	003	Feb 25, 2011	Feb NEWA

TORSEMIDE

TABLET; ORAL
TORSEMIDE

>A>	AB		VINTAGE PHARMS	5MG	A090613	001	Mar 22, 2011	Mar NEWA
>A>	AB			10MG	A090613	002	Mar 22, 2011	Mar NEWA
>A>	AB			20MG	A090613	003	Mar 22, 2011	Mar NEWA
>A>	AB			100MG	A090613	004	Mar 22, 2011	Mar NEWA

TRAMADOL HYDROCHLORIDE

TABLET; ORAL
TRAMADOL HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	50MG	A090404	001	Jan 31, 2011	Jan	NEWA

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
TRIMETHOBENZAMIDE HYDROCHLORIDE

AP	PHARMAFORCE	100MG/ML	A091330	001	Mar 08, 2011	Feb	NEWA

TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE

AP	PHARMAFORCE	100MG/ML	A091329	001	Mar 08, 2011	Feb	NEWA

TRIMIPRAMINE MALEATE

CAPSULE; ORAL
TRIMIPRAMINE MALEATE

AB	MIKAH PHARMA	EQ 25MG BASE	A077361	001	Aug 02, 2006	Feb	CAHN
AB		EQ 50MG BASE	A077361	002	Aug 02, 2006	Feb	CAHN
AB		EQ 100MG BASE	A077361	003	Aug 02, 2006	Feb	CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL
VALACYCLOVIR HYDROCHLORIDE

AB	ACTAVIS PHARMA	EQ 500MG BASE	A090370	001	Mar 16, 2011	Feb	NEWA
AB		EQ 1GM BASE	A090370	002	Mar 16, 2011	Feb	NEWA

VILAZODONE HYDROCHLORIDE

TABLET; ORAL
VIIBRYD

	TROVIS PHARMS	10MG	N022567	001	Jan 21, 2011	Jan	NEWA
		20MG	N022567	002	Jan 21, 2011	Jan	NEWA
+		40MG	N022567	003	Jan 21, 2011	Jan	NEWA

VINCRISTINE SULFATE

INJECTABLE; INJECTION
VINCRISTINE SULFATE

	@ APP PHARMS	1MG/ML	A076401	001	Oct 28, 2003	Jan	DISC

ZIDOVUDINE

INJECTABLE; INJECTION
ZIDOVUDINE

AP	LUITPOLD	10MG/ML	A091457	001	May 06, 2010	Feb	CAHN

TABLET; ORAL
ZIDOVUDINE

	@ MATRIX LABS LTD	100MG	N200732	001	Feb 23, 2011	Feb	NEWA

ZOLPIDEM TARTRATE

TABLET; ORAL
ZOLPIDEM TARTRATE

AB	MYLAN	5MG	A078016	001	Apr 23, 2007	Feb	CAHN
AB		10MG	A078016	002	Apr 23, 2007	Feb	CAHN

FAMOTIDINE

TABLET; ORAL
FAMOTIDINE
MYLAN 10MG A075674 001 Dec 21, 2001 Feb CAHN

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL
CHILDREN'S ALLEGRA ALLERGY
\+ SANOFI AVENTIS US 30MG/5ML N201373 001 Jan 24, 2011 Jan NEWA
CHILDREN'S ALLEGRA HIVES
\+ SANOFI AVENTIS US 30MG/5ML N201373 002 Jan 24, 2011 Jan NEWA

TABLET, ORALLY DISINTEGRATING; ORAL
CHILDREN'S ALLEGRA ALLERGY
\+ SANOFI AVENTIS US 30MG N021909 002 Jan 24, 2011 Jan NEWA
CHILDREN'S ALLEGRA HIVES
\+ SANOFI AVENTIS US 30MG N021909 003 Jan 24, 2011 Jan NEWA

TABLET; ORAL
ALLEGRA ALLERGY
SANOFI AVENTIS US 60MG N020872 007 Jan 24, 2011 Jan NEWA
\+ 180MG N020872 010 Jan 24, 2011 Jan NEWA
ALLEGRA HIVES
SANOFI AVENTIS US 60MG N020872 008 Jan 24, 2011 Jan NEWA
\+ 180MG N020872 009 Jan 24, 2011 Jan NEWA
CHILDREN'S ALLEGRA ALLERGY
SANOFI AVENTIS US 30MG N020872 005 Jan 24, 2011 Jan NEWA
CHILDREN'S ALLEGRA HIVES
SANOFI AVENTIS US 30MG N020872 006 Jan 24, 2011 Jan NEWA
>A> CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY
>A> DR REDDYS LABS LTD 30MG A076502 004 Apr 12, 2011 Mar NEWA
>A> TEVA 30MG A076447 004 Apr 13, 2011 Mar NEWA
>A> CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES
>A> DR REDDYS LABS LTD 30MG A076502 005 Apr 12, 2011 Mar NEWA
>A> TEVA 30MG A076447 005 Apr 13, 2011 Mar NEWA
>A> FEXOFENADINE HYDROCHLORIDE ALLERGY
>A> DR REDDYS LABS LTD 60MG A076502 006 Apr 12, 2011 Mar NEWA
>A> 180MG A076502 008 Apr 12, 2011 Mar NEWA
>A> TEVA 60MG A076447 006 Apr 13, 2011 Mar NEWA
>A> 180MG A076447 008 Apr 13, 2011 Mar NEWA
>A> FEXOFENADINE HYDROCHLORIDE HIVES
>A> DR REDDYS LABS LTD 60MG A076502 007 Apr 12, 2011 Mar NEWA
>A> 180MG A076502 009 Apr 12, 2011 Mar NEWA
>A> TEVA 60MG A076447 007 Apr 13, 2011 Mar NEWA
>A> 180MG A076447 009 Apr 13, 2011 Mar NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION
\+ SANOFI AVENTIS US 60MG;120MG N020786 002 Jan 24, 2011 Jan NEWA
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION
\+ SANOFI AVENTIS US 180MG;240MG N021704 002 Jan 24, 2011 Jan NEWA

IBUPROFEN

TABLET; ORAL

IBUPROFEN

	MARKSANS PHARMA	200MG	A091237	001	Feb 08, 2011	Jan	NEWA
		200MG	A091239	001	Feb 01, 2011	Jan	NEWA
	MERRO PHARM	200MG	A070985	001	Oct 02, 1987	Jan	CAHN
>A>	SVADS HOLDINGS SA	200MG	A079129	001	Mar 28, 2011	Mar	NEWA
>A>		200MG	A091355	001	Apr 04, 2011	Mar	NEWA

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

NOVOLIN N

+	NOVO NORDISK INC	100 UNITS/ML	N019959	001	Jul 01, 1991	Jan	CRLD

LEVONORGESTREL

TABLET; ORAL

PLAN B

+	TEVA WOMENS	0.75MG	N021045	002	Aug 24, 2006	Feb	CAHN

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

	MARKSANS PHARMA	EQ 200MG BASE	A090545	001	Mar 16, 2011	Feb	NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

	MYLAN	EQ 75MG BASE	A075497	001	Jan 14, 2000	Feb	CAHN

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 3 MARCH 2011

NO MARCH 2011 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

http://www.fda.gov/orphan/designat/list.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO MARCH 2011 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2011

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ADAPALENE - DIFFERIN							
N021753	001	7868044	Mar 12, 2023	U-1078			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO							
N022545	001					NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO							
N022545	002					NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO							
N022545	003					NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO							
N022545	004					NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE							
N200045	001	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE							
N200045	002	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE							
N200045	003	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE							
N200045	004	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE							
N200045	005	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
ALVIMOPAN - ENTEREG							
N021775	001	5250542	Mar 29, 2016	DS DP U-878			
AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE							
A078381	005					PC	Jul 02, 2011
AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE							
A078381	006					PC	Jul 02, 2011
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 10							
N021303	001	RE42096	Oct 21, 2018	DP			
		RE42096*PED	Apr 21, 2019				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 15							
N021303	006	RE42096	Oct 21, 2018	DP			
		RE42096*PED	Apr 21, 2019				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 20							
N021303	002	RE42096	Oct 21, 2018	DP			
		RE42096*PED	Apr 21, 2019				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 25							
N021303	004	RE42096	Oct 21, 2018	DP			
		RE42096*PED	Apr 21, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 30						
N021303 003	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 5						
N021303 005	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
ARIPIPRAZOLE - ABILIFY						
N021436 001					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021436 002					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021436 003					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021436 004					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021436 005					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021436 006					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021713 001					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021729 002					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021729 003					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021866 001					I-633	Feb 16, 2014
ATAZANAVIR SULFATE - REYATAZ						
N021567 001					D-130	Feb 04, 2014
ATAZANAVIR SULFATE - REYATAZ						
N021567 002					D-130	Feb 04, 2014
ATAZANAVIR SULFATE - REYATAZ						
N021567 003					D-130	Feb 04, 2014
ATAZANAVIR SULFATE - REYATAZ						
N021567 004					D-130	Feb 04, 2014
AZILSARTAN MEDOXOMIL - EDARBI						
N200796 001	5583141	Dec 10, 2013	DS DP U-3		NCE	Feb 25, 2016
	5736555	Jun 25, 2012	DS DP U-3			
	5958961	Jun 06, 2014	DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2011

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AZILSARTAN MEDOXOMIL - EDARBI							
N200796	002	5583141	Dec 10, 2013	DS DP U-3		NCE	Feb 25, 2016
		5736555	Jun 25, 2012	DS DP U-3			
		5958961	Jun 06, 2014	DP U-3			
		7157584	May 22, 2025	DS			
		7572920	Jan 07, 2025	DP U-3			
AZITHROMYCIN - ZMAX							
N050797	001	7887844	Feb 14, 2024	DP			
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT							
N021929	002	>A> 7897646	Sep 09, 2018	U-1118			
CELECOXIB - CELEBREX							
N020998	001	5760068	Jun 02, 2015	U-672			
CELECOXIB - CELEBREX							
N020998	002	5760068	Jun 02, 2015	U-672			
CELECOXIB - CELEBREX							
N020998	003	5760068	Jun 02, 2015	U-672			
CINACALCET HYDROCHLORIDE - SENSIPAR							
N021688	001					I-634	Feb 25, 2014
						M-101	Feb 25, 2014
						>A> ODE	Feb 25, 2018
CINACALCET HYDROCHLORIDE - SENSIPAR							
N021688	002					I-634	Feb 25, 2014
						M-101	Feb 25, 2014
						>A> ODE	Feb 25, 2018
CINACALCET HYDROCHLORIDE - SENSIPAR							
N021688	003					I-634	Feb 25, 2014
						M-101	Feb 25, 2014
						>A> ODE	Feb 25, 2018
CLOPIDOGREL BISULFATE - PLAVIX							
N020839	001	4847265	Nov 17, 2011	DS DP			
		4847265*PED	May 17, 2012				
		5576328	Jan 31, 2014	U-432	Y		
		5576328*PED	Jul 31, 2014				
		6429210	Jun 10, 2019	DS DP			
		6429210*PED	Dec 10, 2019				
		6504030	Jun 10, 2019	DS			
		6504030*PED	Dec 10, 2019				
CLOPIDOGREL BISULFATE - PLAVIX							
N020839	002	4847265	Nov 17, 2011	DS DP			
		4847265*PED	May 17, 2012				
		6429210	Jun 10, 2019	DS DP			
		6429210*PED	Dec 10, 2019				
		6504030	Jun 10, 2019	DS			
		6504030*PED	Dec 10, 2019				
COLCHICINE - COLCRYS							
N022352	001	>A> 7906519	Feb 17, 2029	U-1116			
		>A> 7915269	Feb 17, 2029	U-1007			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2011

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DESIRUDIN RECOMBINANT - IPRIVASK							
N021271 001		6103515	Aug 15, 2017	DS			
DICLOFENAC POTASSIUM - ZIPSOR							
N022202 001		7884095	Feb 24, 2029			U-1111	
		7884095*PED	Aug 24, 2029				
DIENOGEST; ESTRADIOL VALERATE - NATAZIA							
N022252 001	**>A>**	6133251	Oct 25, 2016	DP		U-828	
	>A>	6133251	Oct 25, 2016	DP		U-112	
	>A>	6133251	Oct 25, 2016	DP		U-1	
	>A>	6884793	Oct 25, 2016	DP			
DORIPENEM - DORIBAX							
N022106 001		5317016	Jun 05, 2015	DS DP		U-282	
DORIPENEM - DORIBAX							
N022106 002		5317016	Jun 05, 2015	DS DP		U-282	
DOXEPIN HYDROCHLORIDE - SILENOR							
N022036 001	**>A>**	7915307	Aug 24, 2027			U-620	
DOXEPIN HYDROCHLORIDE - SILENOR							
N022036 002	**>A>**	7915307	Aug 24, 2027			U-620	
DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL							
N022574 001		5798338	Jul 10, 2015	DP			
		6441168	Apr 17, 2020	DS			
		6958326	Dec 20, 2021	DP			
		7163931	Mar 03, 2022			U-1	
ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO							
N022511 001		5714504	Feb 03, 2015	DP		U-1053	
		5714504*PED	Aug 03, 2015				
		5900424	May 04, 2016	DS		U-1053	
		5900424*PED	Nov 04, 2016				
		6369085	May 25, 2018	DS DP		U-1053	
		6369085*PED	Nov 25, 2018				
		6875872	May 27, 2014	DS			
		6875872*PED	Nov 27, 2014				
		7411070	May 25, 2018	DS		U-1053	
		7411070*PED	Nov 25, 2018				
ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO							
N022511 002		5714504	Feb 03, 2015	DP		U-1053	
		5714504*PED	Aug 03, 2015				
		5900424	May 04, 2016	DS		U-1053	
		5900424*PED	Nov 04, 2016				
		6369085	May 25, 2018	DS DP		U-1053	
		6369085*PED	Nov 25, 2018				
		6875872	May 27, 2014	DS			
		6875872*PED	Nov 27, 2014				
		7411070	May 25, 2018	DS		U-1053	
		7411070*PED	Nov 25, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2011

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ETHINYL ESTRADIOL; LEVONORGESTREL - LOSEASONIQUE							
N022262 001	>A>	7855190	Dec 05, 2028	U-1			
		7858605	Jun 23, 2023	DP			
ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE							
N021840 001	>A>	7855190	Dec 05, 2028	U-1			
		7858605	Jun 23, 2023	DP			
ETHINYL ESTRADIOL; NORETHINDRONE - NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
N022573 001		5552394	Jul 22, 2014	U-828			
		6667050	Apr 06, 2019	DP U-828			
ETRAVIRINE - INTELENCE							
N022187 001		7887845	Mar 25, 2019	DP			
ETRAVIRINE - INTELENCE							
N022187 002		6878717	Nov 05, 2019	U-1016		NCE	Jan 18, 2013
		7037917	Nov 05, 2019	DS DP U-1016			
		7887845	Mar 25, 2019	DP			
EVEROLIMUS - AFINITOR							
N022334 001						>A> ODE	Oct 29, 2017
EVEROLIMUS - AFINITOR							
N022334 002						>A> ODE	Oct 29, 2017
EVEROLIMUS - AFINITOR							
N022334 003						>A> NCE	Mar 30, 2014
						>A> ODE	Oct 29, 2017
EXENATIDE SYNTHETIC - BYETTA							
N021773 001		5424286	Dec 01, 2016	U-653			
		5424286	Dec 01, 2016	U-1108			
EXENATIDE SYNTHETIC - BYETTA							
N021773 002		5424286	Dec 01, 2016	U-653			
		5424286	Dec 01, 2016	U-1108			
FAMCICLOVIR - FAMVIR							
N020363 001						M-98	Jan 31, 2014
FAMCICLOVIR - FAMVIR							
N020363 002						M-98	Jan 31, 2014
FAMCICLOVIR - FAMVIR							
N020363 003						M-98	Jan 31, 2014
FENOFIBRATE - ANTARA (MICRONIZED)							
N021695 001		7863331	Aug 08, 2020	U-1107			
		7863331	Aug 08, 2020	U-1106			
FENOFIBRATE - ANTARA (MICRONIZED)							
N021695 003		7863331	Aug 08, 2020	U-1107			
		7863331	Aug 08, 2020	U-1106			
FENOFIBRIC ACID - FIBRICOR							
N022418 001	>A>	7915247	Aug 20, 2027	U-1061			
	>A>	7915247	Aug 20, 2027	U-1059			
	>A>	7915247	Aug 20, 2027	U-1000			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2011

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENOFIBRIC ACID - FIBRICOR							
N022418 002	>A>	7915247	Aug 20, 2027	U-1061			
	>A>	7915247	Aug 20, 2027	U-1059			
	>A>	7915247	Aug 20, 2027	U-1000			
FENTANYL CITRATE - ABSTRAL							
N022510 001		6759059	Sep 24, 2019	DP U-767			
		6761910	Sep 24, 2019	DP U-767			
	>A>	7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL							
N022510 002		6759059	Sep 24, 2019	DP U-767			
		6761910	Sep 24, 2019	DP U-767			
	>A>	7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL							
N022510 003		6759059	Sep 24, 2019	DP U-767			
		6761910	Sep 24, 2019	DP U-767			
	>A>	7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL							
N022510 004		6759059	Sep 24, 2019	DP U-767			
		6761910	Sep 24, 2019	DP U-767			
	>A>	7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL							
N022510 005		6759059	Sep 24, 2019	DP U-767			
		6761910	Sep 24, 2019	DP U-767			
	>A>	7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL							
N022510 006		6759059	Sep 24, 2019	DP U-767			
		6761910	Sep 24, 2019	DP U-767			
	>A>	7910132	Sep 24, 2019	DP U-767			
FERUMOXYTOL - FERAHEME							
N022180 001		7871597	Mar 08, 2020	DS DP			
FESOTERODINE FUMARATE - TOVIAZ							
N022030 001		7855230	May 11, 2019	U-913			
FESOTERODINE FUMARATE - TOVIAZ							
N022030 002		7855230	May 11, 2019	U-913			
FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE							
A079043 001						PC	Jul 27, 2011
FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA							
N021112 001	>A>	7915243	Mar 22, 2026	DP			
FULVESTRANT - FASLODEX							
N021344 001		6774122	Jan 09, 2021	U-596		D-126	Sep 09, 2013
		6774122*PED	Jul 09, 2021			PED	Mar 09, 2014
		7456160	Jan 09, 2021	U-596			
		7456160*PED	Jul 09, 2021				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GABAPENTIN - GABAPENTIN						
A078974 001					PC	Aug 22, 2011
GABAPENTIN - GRALISE						
N022544 001	**>A>** 6340475	Sep 19, 2016	DP		NP	Jan 28, 2014
	>A> 6488962	Jun 20, 2020	DP			
	>A> 6635280	Sep 19, 2016	DP			
	>A> 6723340	Oct 25, 2021	DP			
	>A> 7438927	Feb 26, 2024	U-1114			
	>A> 7731989	Oct 25, 2022	DP			
GABAPENTIN - GRALISE						
N022544 002	**>A>** 6340475	Sep 19, 2016	DP		NP	Jan 28, 2014
	>A> 6488962	Jun 20, 2020	DP			
	>A> 6635280	Sep 19, 2016	DP			
	>A> 6723340	Oct 25, 2021	DP			
	>A> 7438927	Feb 26, 2024	U-1114			
	>A> 7731989	Oct 25, 2022	DP			
GADOBUTROL - GADAVIST						
N201277 001	**>A>** 5980864	Nov 09, 2016	DS DP U-1119		**>A>** NCE	Mar 14, 2016
GADOBUTROL - GADAVIST						
N201277 002	**>A>** 5980864	Nov 09, 2016	DS DP U-1119		**>A>** NCE	Mar 14, 2016
GADOBUTROL - GADAVIST						
N201277 003	**>A>** 5980864	Nov 09, 2016	DS DP U-1119		**>A>** NCE	Mar 14, 2016
GADOBUTROL - GADAVIST						
N201277 004	**>A>** 5980864	Nov 09, 2016	DS DP U-1119		**>A>** NCE	Mar 14, 2016
GADOBUTROL - GADAVIST						
N201277 005	**>A>** 5980864	Nov 09, 2016	DS DP U-1119		**>A>** NCE	Mar 14, 2016
GADOFOSVESET TRISODIUM - ABLAVAR						
N021711 001	**>A>** 5362475	Nov 08, 2011	DS			
	>A> 6676929	May 26, 2015	DP			
	>A> 7011815	Feb 01, 2015	U-1112			
	>A> 7060250	May 26, 2015	DS			
	>A> 7229606	May 26, 2015	U-1112			
GADOFOSVESET TRISODIUM - ABLAVAR						
N021711 002	**>A>** 5362475	Nov 08, 2011	DS			
	>A> 6676929	May 26, 2015	DP			
	>A> 7011815	Feb 01, 2015	U-1112			
	>A> 7060250	May 26, 2015	DS			
	>A> 7229606	May 26, 2015	U-1112			
GEMCITABINE HYDROCHLORIDE - GEMCITABINE						
A079183 001					PC	May 14, 2011
GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE						
A077983 001					PC	Jul 24, 2011
GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE						
A077983 002					PC	Jul 24, 2011
GUANFACINE HYDROCHLORIDE - INTUNIV						
N022037 001					I-635	Feb 25, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GUANFACINE HYDROCHLORIDE - INTUNIV						
N022037 002					I-635	Feb 25, 2014
GUANFACINE HYDROCHLORIDE - INTUNIV						
N022037 003					I-635	Feb 25, 2014
GUANFACINE HYDROCHLORIDE - INTUNIV						
N022037 004					I-635	Feb 25, 2014
HYDROXYPROGESTERONE CAPROATE - MAKENA						
N021945 001					ODE	Feb 03, 2018
IMIQUIMOD - ZYCLARA						
N022483 001					**>A>** I-636	Mar 24, 2014
INSULIN RECOMBINANT HUMAN - HUMULIN R						
N018780 001					**>A>** NR	Mar 25, 2014
INSULIN RECOMBINANT HUMAN - HUMULIN R PEN						
N018780 005					**>A>** NR	Mar 25, 2014
IOFLUPANE I-123 - DATSCAN						
N022454 001					NCE	Jan 14, 2016
IXABEPILONE - IXEMPRA KIT						
N022065 001	**>A>** 6670384	Jan 23, 2022	DP U-960		**>A>** NCE	Oct 16, 2012
	>A> 6670384	Jan 23, 2022	DP U-959		**>A>** PED	Apr 16, 2013
	>A> 6670384*PED	Jul 23, 2022				
	>A> 7022330	Jan 23, 2022	DP U-958			
	>A> 7022330*PED	Jul 23, 2022				
	>A> 7125899	May 26, 2018	DS DP U-957			
	>A> 7125899*PED	Nov 26, 2018				
	>A> 7312237	Aug 21, 2024	U-965			
	>A> 7312237*PED	Feb 21, 2025				
	>A> RE41393	Feb 08, 2022	U-961			
	>A> RE41393*PED	Aug 08, 2022				
	>A> RE41911	May 26, 2018	DS DP U-961			
	>A> RE41911*PED	Nov 26, 2018				
IXABEPILONE - IXEMPRA KIT						
N022065 002	**>A>** 6670384	Jan 23, 2022	DP U-960		**>A>** NCE	Oct 16, 2012
	>A> 6670384	Jan 23, 2022	DP U-959		**>A>** PED	Apr 16, 2013
	>A> 6670384*PED	Jul 23, 2022				
	>A> 7022330	Jan 23, 2022	DP U-958			
	>A> 7022330*PED	Jul 23, 2022				
	>A> 7125899	May 26, 2018	DS DP U-957			
	>A> 7125899*PED	Nov 26, 2018				
	>A> 7312237	Aug 21, 2024	U-965			
	>A> 7312237*PED	Feb 21, 2025				
	>A> RE41393	Feb 08, 2022	U-961			
	>A> RE41393*PED	Aug 08, 2022				
	>A> RE41911	May 26, 2018	DS DP U-961			
	>A> RE41911*PED	Nov 26, 2018				
LANREOTIDE ACETATE - SOMATULINE DEPOT						
N022074 001	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LANREOTIDE ACETATE - SOMATULINE DEPOT						
N022074 002	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
LANREOTIDE ACETATE - SOMATULINE DEPOT						
N022074 003	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
LANSOPRAZOLE - PREVACID						
N021428 001	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
LANSOPRAZOLE - PREVACID						
N021428 002	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
LENALIDOMIDE - REVLIMID						
N021880 001	7855217	Nov 24, 2024	DS DP			
LENALIDOMIDE - REVLIMID						
N021880 002	7855217	Nov 24, 2024	DS DP			
LENALIDOMIDE - REVLIMID						
N021880 004	7855217	Nov 24, 2024	DS DP			
METFORMIN HYDROCHLORIDE - FORTAMET						
N021574 001	**>A>** 7919116	Mar 20, 2018	DP			
METFORMIN HYDROCHLORIDE - FORTAMET						
N021574 002	**>A>** 7919116	Mar 20, 2018	DP			
METRONIDAZOLE - VANDAZOLE						
N021806 001	7456207	Sep 22, 2024	DP			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N022256 001	7888342	Nov 05, 2021			U-882	
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N022256 002	7888342	Nov 05, 2021			U-882	
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N022256 003	7888342	Nov 05, 2021			U-882	
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N022256 004	7888342	Nov 05, 2021			U-882	
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 001	**>A>** 7919483	Feb 28, 2027			U-1078	
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 002	**>A>** 7919483	Feb 28, 2027			U-1078	
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 003	**>A>** 7919483	Feb 28, 2027			U-1078	
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 004	**>A>** 7919483	Feb 28, 2027			U-1078	
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 005	**>A>** 7919483	Feb 28, 2027			U-1078	

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 006	**>A>** 7919483	Feb 28, 2027	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 007	**>A>** 7919483	Feb 28, 2027	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 008	**>A>** 7919483	Feb 28, 2027	U-1078			
MOMETASONE FUROATE MONOHYDRATE - NASONEX						
N020762 001					M-99	Jan 19, 2014
NEVIRAPINE - VIRAMUNE XR						
N201152 001	**>A>** 5366972	Nov 22, 2011	DS DP U-167		**>A>** NDF	Mar 25, 2014
	>A> 5366972*PED	May 22, 2012				
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N021087 001	**>A>** 5952375	Feb 27, 2015	DS DP			
	>A> 5952375*PED	Aug 27, 2015				
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N021087 002	**>A>** 5952375	Feb 27, 2015	DS DP			
	>A> 5952375*PED	Aug 27, 2015				
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N021087 003	**>A>** 5952375	Feb 27, 2015	DS DP			
	>A> 5952375*PED	Aug 27, 2015				
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N021246 001	**>A>** 5763483	Dec 27, 2016	DS U-376			
	>A> 5763483	Dec 27, 2016	DS U-1113			
	>A> 5952375	Feb 27, 2015	DS DP			
	>A> 5952375*PED	Aug 27, 2015				
PACLITAXEL - ABRAXANE						
N021660 001	**>A>** RE41884	Aug 14, 2016	U-1117			
PEMETREXED DISODIUM - ALIMTA						
N021462 001					**>A>** M-61	Mar 17, 2014
					>A> PED	Sep 17, 2014
PEMETREXED DISODIUM - ALIMTA						
N021462 002					**>A>** M-61	Mar 17, 2014
					>A> PED	Sep 17, 2014
PERFLUTREN - DEFINITY						
N021064 001	**>A>** 5527521	Feb 22, 2015	DP U-665			
	5585112	Dec 17, 2013	DP			
PLERIXAFOR - MOZOBIL						
N022311 001	**>A>** 7897590	Jul 22, 2023	U-936			
	RE42152	Dec 10, 2013	DP			
RALTEGRAVIR POTASSIUM - ISENTRESS						
N022145 001	7169780	Oct 03, 2023	DS DP			
RANOLAZINE - RANEXA						
N021526 001	**>A>** 6369062	May 27, 2019	DP	Y		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RETAPAMULIN - ALTABAX						
N022055 001	7875630	Feb 14, 2027	DS			
	RE39128	Apr 12, 2021	DS DP U-805			
RIFAXIMIN - XIFAXAN						
N021361 001	**>A>** 7902206	Jun 19, 2024	DS DP			
	>A> 7906542	Jun 01, 2025	DS DP			
RIFAXIMIN - XIFAXAN						
N022554 001	**>A>** 7612199	Jun 19, 2024	DS DP			
	>A> 7902206	Jun 19, 2024	DS DP			
	>A> 7906542	Jun 01, 2025	DS DP			
RIZATRIPTAN BENZOATE - MAXALT						
N020864 001	**>A>** 5602162	Feb 11, 2014		Y		
RIZATRIPTAN BENZOATE - MAXALT						
N020864 002	**>A>** 5602162	Feb 11, 2014		Y		
RIZATRIPTAN BENZOATE - MAXALT-MLT						
N020865 001	**>A>** 5602162	Feb 11, 2014	U-240	Y		
RIZATRIPTAN BENZOATE - MAXALT-MLT						
N020865 002	**>A>** 5602162	Feb 11, 2014	U-240	Y		
ROFLUMILAST - DALIRESP						
N022522 001	**>A>** 5712298	Jan 27, 2015	DS DP U-1115		NCE	Feb 28, 2016
RUFINAMIDE - BANZEL						
N201367 001	**>A>** 6740669	Aug 17, 2020	DS DP		**>A>** NCE **>A>** ODE	Nov 14, 2013 Nov 14, 2015
SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE						
N201444 001					ODE	Jan 14, 2018
SODIUM OXYBATE - XYREM						
N021196 001	7668730	Jun 16, 2024	U-1110			
	7895059	Dec 17, 2022	U-1110			
SORAFENIB TOSYLATE - NEXAVAR						
N021923 001	**>A>** 7897623	Jan 12, 2020	DP			
SPINOSAD - NATROBA						
N022408 001	5496931	Mar 05, 2013	DS U-1105		NCE	Jan 18, 2016
	6063771	Jun 22, 2019	DP U-1105			
	6342482	Jun 22, 2019	DP U-1105			
	7030095	Jul 02, 2021	DP U-1105			
SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO						
N022239 001	7776007	Apr 09, 2025	DP			
	>A> 7901385	Jul 31, 2026	DP			
TELBIVUDINE - TYZEKA						
N022011 001	7858594	Sep 11, 2023	DS DP U-999			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
THALIDOMIDE - THALOMID						
N020785 001	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
THALIDOMIDE - THALOMID						
N020785 002	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
THALIDOMIDE - THALOMID						
N020785 003	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
THALIDOMIDE - THALOMID						
N020785 004	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
TIGECYCLINE - TYGACIL						
N021821 001	7879828	Feb 05, 2029	DP			
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N022567 001	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N022567 002	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N022567 003	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE						
A078148 001					PC	Jun 04, 2011

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
3. **** The expiration date for U.S. Patent No. 5,608,075 is March 4, 2009.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 31st Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm